<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors - Smith, GA - 2014 | Cochrane Library</title> <meta content="Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors - Smith, GA - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009532.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors - Smith, GA - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009532.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009532.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors" name="citation_title"/> <meta content="Graham A Smith" name="citation_author"/> <meta content="Barnet and Chase Farm NHS Hospitals Trust" name="citation_author_institution"/> <meta content="Sheila A Fisher" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Carolyn Doree" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Emanuele Di Angelantonio" name="citation_author"/> <meta content="University of Cambridge" name="citation_author_institution"/> <meta content="David J Roberts" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="david.roberts@ndcls.ox.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD009532.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/07/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009532.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009532.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009532.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Iron Deficiencies; Anemia, Iron‐Deficiency [blood, etiology, *prevention &amp; control]; Blood Donors [*statistics &amp; numerical data]; Constipation [etiology]; Ferritins [blood]; Hemoglobin A [analysis]; Iron [blood]; Iron, Dietary [*administration &amp; dosage, adverse effects]; Randomized Controlled Trials as Topic; Sex Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009532.pub2&amp;doi=10.1002/14651858.CD009532.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="18M35a5z";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009532\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009532\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009532.pub2",title:"Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors",firstPublishedDate:"Jul 3, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Injuries Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009532.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009532.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009532.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009532.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009532.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009532.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009532.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009532.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009532.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009532.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3280 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009532.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0128"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-sec-0122"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/appendices#CD009532-sec-0133"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/table_n/CD009532StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/table_n/CD009532StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#CD009532-cr-0002">Graham A Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#CD009532-cr-0003">Sheila A Fisher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#CD009532-cr-0004">Carolyn Doree</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#CD009532-cr-0005">Emanuele Di Angelantonio</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information#CD009532-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>David J Roberts</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information/en#CD009532-sec-0148">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 July 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009532.pub2">https://doi.org/10.1002/14651858.CD009532.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009532-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009532-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009532-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009532-abs-0007">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009532-abs-0001" lang="en"> <section id="CD009532-sec-0001"> <h3 class="title" id="CD009532-sec-0001">Background</h3> <p>Iron deficiency is a significant cause of deferral in people wishing to donate blood. If iron removed from the body through blood donation is not replaced, then donors may become iron deficient. All donors are screened at each visit for low haemoglobin (Hb) levels. However, some deferred blood donors do not return to donate. Deferred first‐time donors are even less likely to return. Interventions that reduce the risk of provoking iron deficiency and anaemia in blood donors will therefore increase the number of blood donations. Currently, iron supplementation for blood donors is not a standard of care in many blood services. A systematic review is required to answer specific questions regarding the efficacy and safety of iron supplementation in blood donors. </p> </section> <section id="CD009532-sec-0002"> <h3 class="title" id="CD009532-sec-0002">Objectives</h3> <p>To assess the efficacy and safety of iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. </p> </section> <section id="CD009532-sec-0003"> <h3 class="title" id="CD009532-sec-0003">Search methods</h3> <p>We ran the search on 18 November 2013. We searched Cochrane Injuries Group Specialised Register, CENTRAL, PubMed, MEDLINE (OvidSP), EMBASE (OvidSP), CINAHL (EBSCO Host) and six other databases. We also searched clinical trials registers and screened guidelines reference lists. </p> </section> <section id="CD009532-sec-0004"> <h3 class="title" id="CD009532-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) comparing iron supplementation versus placebo or control, oral versus parenteral iron supplementation, iron supplementation versus iron‐rich food supplements, and different doses, treatment durations and preparations of iron supplementation in healthy blood donors. Autologous blood donors were excluded. </p> </section> <section id="CD009532-sec-0005"> <h3 class="title" id="CD009532-sec-0005">Data collection and analysis</h3> <p>We combined data using random‐effects meta‐analyses. We evaluated heterogeneity using the I<sup>2</sup> statistic; we explored considerable heterogeneity (I<sup>2</sup> &gt; 75%) in subgroup analyses. We carried out sensitivity analyses to assess the impact of trial quality on the results. </p> </section> <section id="CD009532-sec-0006"> <h3 class="title" id="CD009532-sec-0006">Main results</h3> <p>Thirty RCTs (4704 participants) met the eligibility criteria, including 19 comparisons of iron supplementation and placebo or control; one comparison of oral and parenteral iron supplementation; four comparisons of different doses of iron supplementation; one comparison of different treatment durations of iron supplementation; and 12 comparisons of different iron supplementation preparations. </p> <p>Many studies were of low or uncertain methodological quality and therefore at high or uncertain risk of bias. We therefore rated the quality of the evidence for our outcomes as moderate. There was a statistically significant reduction in deferral due to low haemoglobin in donors who received iron supplementation compared with donors who received no iron supplementation, both at the first donation visit after commencement of iron supplementation (risk ratio (RR) 0.34; 95% confidence interval (CI) 0.21 to 0.55; four studies; 1194 participants; P value &lt; 0.0001) and at subsequent donations (RR 0.25; 95% CI 0.15 to 0.41; three studies; 793 participants; P value &lt; 0.00001). Supplementation also resulted in significantly higher haemoglobin levels (mean difference (MD) 2.36 g/L; 95% CI 0.06 to 4.66; eight studies; 847 participants, P value =0.04), and iron stores, including serum ferritin (MD 13.98 ng/mL; 95% CI 8.92 to 19.03; five studies; 640 participants; P value &lt; 0.00001) and transferrin saturation (MD 3.91%; 95% CI 2.02 to 5.80; four studies; 344 participants; P value &lt; 0.0001) prior to further donation. The differences were maintained after subsequent donation(s). </p> <p>Adverse effects were widely reported and were more frequent in donors who received iron supplementation (RR 1.60; 95% CI 1.23 to 2.07; four studies; 1748 participants; P value = 0.0005). Adverse effects included constipation, diarrhoea, nausea, vomiting and taste disturbances, and some participants stopped treatment due to side effects. </p> </section> <section id="CD009532-sec-0007"> <h3 class="title" id="CD009532-sec-0007">Authors' conclusions</h3> <p>There is moderate quality evidence that rates of donor deferral due to low haemoglobin are considerably less in those taking iron supplements compared with those without iron supplementation, both at the first donation visit and at subsequent donation. Iron‐supplemented donors also show elevated haemoglobin and iron stores. These beneficial effects are balanced by more frequent adverse events in donors who receive iron supplementation than in those who do not; this is likely to limit acceptability and compliance. The long‐term effects of iron supplementation without measurement of iron stores are unknown. These considerations are likely to preclude widespread use of iron supplementation by tablets. Blood services may consider targeted use of supplementation in those at greatest risk of iron deficiency, personalised donation intervals and providing dietary advice. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009532-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009532-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD009532-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD009532-abs-0006">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009532-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009532-abs-0005">Hrvatski</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009532-abs-0003" lang="en"> <h3>The effects of iron supplementation on iron deficiency and deferral in blood donors</h3> <p>Iron deficiency can cause symptoms of tiredness. The interval between blood donations is set by independent regulators to minimise iron deficiency in donors. Potential blood donors are screened each time they visit to give blood to see if they have iron deficiency. Donors who do not pass this screening test and so cannot give blood are deferred and asked to delay giving blood, but many of these donors do not return. If blood donors take iron tablets then the risk of becoming iron deficient may be reduced. However, the balance between the benefits of giving iron and the possible side effects is not clear. We have reviewed all the randomised trials testing the benefits of giving blood donors iron. The evidence is current up to November 2013. </p> <p>We found 30 randomised trials of iron supplementation in blood donors with a total of 4704 participants. We found that some of the studies did not report details of their design very well and people in some of the studies left the study early and did not contribute data. Combining the results from four studies, we have shown that around 3% of donors who were given iron supplements were unable to give blood when they next came to donate because the levels of iron in their blood were too low, compared with 10% of donors who did not take iron. More than this, 4% of iron‐supplemented donors were unable to give blood at any future donation due to low iron levels, compared with around 20% of donors not given iron supplementation. </p> <p>However, 29% of donors who took iron tablets experienced side effects compared with 17% of donors who were given dummy tablets. Combined data from two studies showed that the iron‐supplemented donors had nearly five times the chance of stomach upsets and changes in their taste compared to donors who did not take these tablets. </p> <p>Due to the issues around how reliable the studies were, the quality of evidence is moderate and these results could change with more research. </p> <p>Donors can benefit from iron tablets but the rate of side effects is high, which means in practice that giving all donors iron tablets is unlikely to be acceptable and we do not know whether giving iron causes extra problems over a long period of time. Blood services may target iron supplementation at groups or individuals who are at risk of iron deficiency or may try to reduce deferral by adjusting donation intervals to suit the donor's ability to give blood without becoming iron deficient or to give specific dietary advice to donors. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009532-sec-0128" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009532-sec-0128"></div> <h3 class="title" id="CD009532-sec-0129">Implications for practice</h3> <section id="CD009532-sec-0129"> <p>Overall, there is moderate quality evidence that iron supplementation has a substantial effect on reducing the risk of low haemoglobin deferral, but a significant proportion of donors taking iron suffer side effects. Blood services seeking a reduction in the levels of deferral due to low haemoglobin would wish to consider any reasonable methods to prevent iron deficiency, weighing cost against benefits and feasibility. With this in mind, possible courses for future action by blood services would be the targeted use of supplementation at groups or individuals <i>at greater risk of iron deficiency</i>, stratified or personalised donation intervals and/or dietary advice. </p> </section> <h3 class="title" id="CD009532-sec-0130">Implications for research</h3> <section id="CD009532-sec-0130"> <p>The effect of dose and preparation of iron on both efficacy and the frequency of side effects is unclear from the existing studies. Crucially, the studies do not allow any definition of the relationship between dose and duration of iron supplementation and benefits or side effects. These questions would have to be explored, in large‐scale randomised controlled trials (RCTs) or pilot studies, before widespread use of iron supplementation in donors could be considered. Potential differences in methods used to assess biomarkers could be important when interpreting the absolute change in biomarker values (such as ferritin). There is very limited evidence that dietary advice to improve iron store is efficacious and there are no trials of dietary advice in donors. Further work in this area should include RCTs of a range of interventions to determine efficacy precisely. Finally, there are few existing randomised trials of the effects of iron supplementation on the physical capacity and quality of life of blood donors; future studies should include an assessment of these measures in iron‐supplemented donors. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009532-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009532-sec-0015"></div> <div class="table" id="CD009532-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Iron supplementation for iron deficiency and/or anaemia in blood donors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Iron supplementation for iron deficiency and/or anaemia in blood donors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with iron deficiency and/or anaemia in blood donors<br/> <b>Settings:</b> national blood services<br/> <b>Intervention:</b> iron supplementation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Iron supplementation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Low Hb deferral ‐ at first donation visit after commencement of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.34</b> <br/> (0.21 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1194<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> <br/> (22 to 58) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (6 to 15) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> <br/> (50 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Low Hb deferral ‐ after multiple donation visits</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.25</b> <br/> (0.15 to 0.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>793<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (30 to 81) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (8 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> <br/> (68 to 187) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hb (g/L) ‐ before further donation</b> <br/> Scale from: 123 to 152 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ before further donation in the control groups was<br/> <b>135.2 g/L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ before further donation in the intervention groups was<br/> <b>2.36 higher</b> <br/> (0.06 to 4.66 higher)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hb (g/L) ‐ after subsequent donation(s)</b> <br/> Scale from: 127.3 to 129 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ after subsequent donation(s) in the control groups was<br/> <b>127.8 g/L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ after subsequent donation(s) in the intervention groups was<br/> <b>6.37 higher</b> <br/> (2.36 to 10.39 higher)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin (ng/mL) ‐ before further donation</b> <br/> Scale from: 12.9 to 57.8 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ before further donation in the control groups was<br/> <b>21.1 ng/mL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ before further donation in the intervention groups was<br/> <b>13.98 higher</b> <br/> (8.92 to 19.03 higher)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin (ng/mL) ‐ after subsequent donation(s)</b> <br/> Scale from: 18 to 19 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ after subsequent donation(s) in the control groups was<br/> <b>18.6 ng/mL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ after subsequent donation(s) in the intervention groups was<br/> <b>9.01 higher</b> <br/> (5.76 to 12.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (any)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> <br/> (210 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.6</b> <br/> (1.23 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1748<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>Hb:</b> haemoglobin; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risks will depend on study‐specific low haemoglobin deferral thresholds. Low and high control risks correspond to the minimum and maximum control risks in the included studies.<br/> <sup>2</sup>Most of the information is from studies with an unclear risk of bias. All but one study had a high risk of attrition bias and two studies were partially commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>3</sup>The range of scores is based on the lowest and highest estimate of the scores in the control groups in individual trials.<br/> <sup>4</sup>Most of the information is from studies with an unclear risk of bias. Four studies had a high risk of attrition bias, one study received assistance with data analysis from suppliers of the iron supplementation and one study did not blind participants. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>5</sup>Most of the information is from studies with an unclear risk of bias. All studies had a high risk of attrition bias. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>6</sup>Most of the information is from studies with an unclear risk of bias. Two studies had a high risk of attrition bias and one study was partially commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>7</sup>Most of the information is from studies with an unclear risk of bias. All studies had a high risk of attrition bias and one study was partially commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>8</sup>Most of the information is from studies with an unclear risk of bias. Two studies had a high risk of attrition bias. Potential limitations are likely to lower confidence in the estimate of the effect. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009532-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD009532-sec-0016"></div> <section id="CD009532-sec-0017"> <h3 class="title" id="CD009532-sec-0017">Description of the condition</h3> <p>Red blood cells are donated, tested and administered on an industrial scale. In the United Kingdom, in England and North Wales, NHS Blood and Transplant (NHSBT) collects around 1.9 million red cell donations per annum (<a href="./references#CD009532-bbs2-0081" title="NHSBT. Annual Report. http://www.nhsbt.nhs.uk/annualreview/2013. ">NHSBT 2013</a>). Meeting the blood requirements of health services is becoming increasingly difficult because of changes in attitudes in society to donation. Difficulties in meeting demands are compounded by the short supply of particularly useful blood groups such as O rhesus negative, found in 7% of the population, as well as the need to provide blood of specific blood group types in patients who have developed multiple or widely reactive antibodies. This current trend of declining rates of blood donation, combined with an increase in the requirement for blood components, is likely to continue in coming years (<a href="./references#CD009532-bbs2-0087" title="SeifriedE , KlueterH , WeidmannC , StaudenmaierT , SchrezenmeierH , HenschlerR , et al. How much blood is needed?. Vox Sanguinis2011;100(1):10‐21. ">Seifried 2011</a>). </p> <p>Healthy blood donors can donate whole blood (a standard single red cell unit ‐ approximately 450 mL ‐ collected manually), a double‐dose of red cells (two red cell units collected by machine in a process termed apheresis) and platelets (referred to as plateletpheresis). To be able to donate, blood donors have to answer a number of questions regarding their lifestyle, health, risk of infection and travel prior to donation (donor health check ‐ DHC), as well as exceed minimum physical requirements such as weight and haemoglobin (Hb) level. Donors with major illness, recent cold, fever, infection, gastrointestinal upset or who are generally feeling unwell are deferred from donating. Iron deficiency remains a significant cause of morbidity in the general population and in blood donors (<a href="./references#CD009532-bbs2-0066" title="BaartAm , KortWL , MoonsKG , VergouweY . Prediction of low haemoglobin levels in whole blood donors. Vox Sanguinis2001;100(2):204‐11. ">Baart 2011</a>). Up to 5% of new donors cannot be accepted because of low haemoglobin levels and iron deficiency may be responsible for the deferral of a similar percentage of regular donors. </p> <p>Blood donation removes 250 mg of iron from the body and there is considerable individual variation in body stores of iron, in dietary iron and in the intrinsic capacity to absorb and utilise dietary iron. If this iron is not replaced, then donors may become iron deficient or develop frank iron‐deficiency anaemia. NHSBT and other blood services have a duty of care for blood donors, to ensure that harmful effects of donations are avoided. The period since the last donation is inversely associated with the risk of deferral due to low haemoglobin (<a href="./references#CD009532-bbs2-0066" title="BaartAm , KortWL , MoonsKG , VergouweY . Prediction of low haemoglobin levels in whole blood donors. Vox Sanguinis2001;100(2):204‐11. ">Baart 2011</a>). Lower limits for donation intervals are set to minimise iron deficiency in repeat blood donors. Furthermore, all donors are screened for low haemoglobin levels. Failing to pass the haemoglobin screening test from a fingerprick sample of blood corresponding to an haemoglobin level of 135 g/L for males or 125 g/L for females (in the United Kingdom) leads to 'deferral' (i.e. at least temporary rejection from blood donation) (<a href="./references#CD009532-bbs2-0067" title="http://www.legislation.gov.uk/uksi/2005/50/contents/made. 2005 (accessed 18 February 2011). ">Blood Safety and Quality Regulations 2005</a>). A further appointment to donate is arranged after the normal inert‐donation interval, currently 16 weeks for women and 12 weeks for men in England, to allow donors to replenish their iron stores. </p> <p>Although these safeguards to protect donors are essential, they can have an adverse effect on future donor behaviour. We know that deferral is associated with donor non‐return, especially among first‐time donors (<a href="./references#CD009532-bbs2-0068" title="CusterB , ChinnA , HirsclerNV , BuschMP , MurphyEL . The consequence of temporary deferral on future whole blood donation. Transfusion2007;47(8):1514‐23. ">Custer 2007</a>). Moreover, increasingly rigorous donor selection criteria, combined with demographic changes, have reduced the numbers of first‐time donors. It is therefore essential not only to minimise unnecessary deferral, but also to reduce the risk of provoking iron deficiency or anaemia in order to optimise the number of blood donors and donations. </p> <p>A number of markers of iron deficiency have been studied in existing Cochrane reviews, both of iron stores (ferritin) and circulating iron and iron available for erythropoiesis (serum iron, total iron binding concentration (TIBC) and % transferrin saturation). Haemoglobin levels and measures of iron deficiency fall in regular blood donors, particularly in pre‐menopausal women (<a href="./references#CD009532-bbs2-0065" title="Alvarez‐OssorioL , KirchnerH , KluterH , SchlenkeP . Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron‐depletion in regular blood donors. Transfusion Medicine2000;10(2):107‐12. ">Alvarez‐Ossorio 2000</a>; <a href="./references#CD009532-bbs2-0072" title="FinchCA , CookJD , LabbeRF , CulalaM . Effect of blood donation on iron stores as evaluated by serum ferritin. Blood1977;50(3):441‐7. ">Finch 1977</a>; <a href="./references#CD009532-bbs2-0080" title="MilmanN . Serrum ferritin in Danes: studies of iron status from infancy to old age, during blood donation and pregnancy. International Journal of Haematology1996;63(2):103‐35. ">Milman 1996</a>; <a href="./references#CD009532-bbs2-0088" title="SkikneB , LynchS , BorekCD , CookJ . Iron and blood donation. Clinical Haematology1984;13(1):271‐81. ">Skikne 1984</a>; <a href="./references#CD009532-bbs2-0089" title="WorwoodM , DarkeC . Serum ferritin, blood donation, iron stores and haemochromatosis. Transfusion Medicine1993;2(1):21‐8. ">Worwood 1993</a>). Currently, iron supplementation for blood donors is not a standard of care in NHSBT. Interestingly, there is some evidence from existing randomised controlled trials (RCTs) of improvement of exercise tolerance, mood disturbance and restless legs syndrome after treatment of iron‐deficient but non‐anaemic adults (<a href="./references#CD009532-bbs2-0070" title="EarleyCJ , HorskaA , MohamedMA , BarkerPB , BeardJL , AllenRP . A randomized, double‐blind, placebo‐controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Medicine2009;10(2):206‐11. ">Earley 2009</a>; <a href="./references#CD009532-bbs2-0073" title="GroteKL , LeissnerL , HednerJ , UlfbergJ . A randomized, double blind, placebo controlled, multi‐center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Movement Disorders2009;24(10):1445‐52. ">Grote 2009</a>). However, there are at present no formal systematic reviews of the benefits of iron supplementation interventions in terms of improved haemoglobin, iron status, subjective symptoms of fatigue or mood disturbance or cognitive function in blood donors or, of crucial interest to the blood services, of their deferral for low haemoglobin at the next attendance at donor clinics, nor of the adverse effects and costs of these supplementation strategies. </p> <p>In spite of medical, logistic and even ethical problems that may be faced in implementing a programme of iron supplementation for blood donors, a pragmatic review of the benefits and costs for the donor and the blood service is essential to inform policy. A systematic review has been undertaken to answer the specific questions of the efficacy and safety of iron supplementation in blood donors in preventing a fall in haemoglobin, improving iron stores and reducing systemic, neurological or cognitive symptoms in donors. </p> </section> <section id="CD009532-sec-0018"> <h3 class="title" id="CD009532-sec-0018">Description of the intervention</h3> <p>Iron supplementation interventions aim to increase iron stores in blood donors. Iron stores are regulated through absorption of iron and so interventions either directly or indirectly increase iron available for absorption. Interventions may be in the form of dietary advice to increase the amount of iron‐rich food or in the form of oral iron supplementation, such as iron salts. There are a variety of formulations with different side effect profiles in different people. It is also possible to give parenteral (intravenous or intramuscular) iron if iron is poorly absorbed. However, this is unlikely to be an intervention used for blood donors due to a variety of reasons. </p> </section> <section id="CD009532-sec-0019"> <h3 class="title" id="CD009532-sec-0019">How the intervention might work</h3> <p>Iron supplementation interventions aim to increase iron stores in blood donors by increasing iron available for absorption. </p> </section> <section id="CD009532-sec-0020"> <h3 class="title" id="CD009532-sec-0020">Why it is important to do this review</h3> <p>This review is important as maintaining the supply and health of blood donors is imperative for health services. The role of iron supplementation in maintaining the health of donors and their ability to donate is poorly understood and the available evidence has not been synthesised. A systematic review of the current evidence of the efficacy and safety of iron supplementation in blood donors is crucial to inform future trials and policy of iron supplementation in donors. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009532-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009532-sec-0021"></div> <p>To assess the efficacy and safety of iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009532-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009532-sec-0022"></div> <section id="CD009532-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009532-sec-0024"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD009532-sec-0025"> <h4 class="title">Types of participants</h4> <p>Healthy prospective first‐time or repeat blood donors: whole blood donors (standard one unit collection), double‐dose red cell donors and platelet donors (referred to as plateletpheresis). Autologous blood donors (donation of blood for the donor's own use) were excluded. </p> </section> <section id="CD009532-sec-0026"> <h4 class="title">Types of interventions</h4> <p> <ul id="CD009532-list-0001"> <li> <p>Iron supplementation versus placebo/control.</p> </li> <li> <p>Iron supplementation: oral versus parenteral iron supplementation.</p> </li> <li> <p>Iron supplementation versus iron‐rich food supplements (fortified foods with a quantifiable amount of iron). </p> </li> <li> <p>Iron supplementation, dose A versus iron supplementation, dose B.</p> </li> <li> <p>Iron supplementation, treatment duration A versus iron supplementation, treatment duration B. </p> </li> <li> <p>Iron supplementation, preparation A versus iron supplementation, preparation B.</p> </li> </ul> </p> </section> <section id="CD009532-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD009532-sec-0028"> <h5 class="title">Primary outcomes</h5> <p>Risk ratio of deferral of blood donors (number of prospective blood donors who are at least temporarily rejected from blood donation) due to low haemoglobin. </p> <p>The low haemoglobin deferral threshold differs across studies according to the population and sex of the donor studied (see <a href="./references#CD009532-sec-0154" title="">Characteristics of included studies</a>). </p> </section> <section id="CD009532-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD009532-list-0002"> <li> <p>Mean levels of haemoglobin (Hb), mean cell volume (MCV), other blood indices and iron stores before further donations. </p> </li> <li> <p>Mean levels of Hb, mean cell volume (MCV), other blood indices and iron stores after subsequent donations. </p> </li> <li> <p>Health‐related quality of life, especially changes in cognitive function, 'mood' disturbances, aerobic power, fatigue score, physical activity. </p> </li> <li> <p>Adverse effects from interventions received.</p> </li> <li> <p>Compliance.</p> </li> </ul> </p> <p>Analysis of blood indices were restricted to Hb, MCV, serum ferritin, serum or plasma iron, total iron binding capacity (TIBC) and transferrin saturation. We noted other reported blood indices and described these in the <a href="./references#CD009532-sec-0154" title="">Characteristics of included studies</a> tables. </p> </section> </section> </section> <section id="CD009532-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>The SRI's Information Specialist (CD) formulated the search strategies in collaboration with the Cochrane Injuries Group. </p> <p>In order to reduce publication and retrieval bias we did not restrict our search by language, date or publication status. </p> <section id="CD009532-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the following for RCTs and systematic reviews:</p> <p> <ul id="CD009532-list-0003"> <li> <p>Cochrane Injuries Group Specialised Register (December 2013) (<a href="./appendices#CD009532-sec-0134">Appendix 1</a>); </p> </li> <li> <p>CENTRAL (Cochrane Central Register of Controlled Trials (2013, Issue 10) (<a href="./appendices#CD009532-sec-0134">Appendix 1</a>); </p> </li> <li> <p>PubMed (epublications only) (<a href="./appendices#CD009532-sec-0135">Appendix 2</a>); </p> </li> <li> <p>MEDLINE (OvidSP) (1948 to 18 November 2013) (<a href="./appendices#CD009532-sec-0136">Appendix 3</a>); </p> </li> <li> <p>EMBASE (OvidSP) (1974 to 18 November 2013) (<a href="./appendices#CD009532-sec-0137">Appendix 4</a>); </p> </li> <li> <p>CINAHL (EBSCO Host) (1982 to 18 November 2013) (<a href="./appendices#CD009532-sec-0138">Appendix 5</a>); </p> </li> <li> <p>British Nursing Index and Archive (1985 to 18 November 2013) (<a href="./appendices#CD009532-sec-0139">Appendix 6</a>); </p> </li> <li> <p>Transfusion Evidence Library (1980 to 18 November 2013) (<a href="./appendices#CD009532-sec-0140">Appendix 7</a>); </p> </li> <li> <p>LILACS (1982 to 18 November 2013) (<a href="./appendices#CD009532-sec-0141">Appendix 8</a>); </p> </li> <li> <p>IndMed (1985 to 18 November 2013) (<a href="./appendices#CD009532-sec-0142">Appendix 9</a>); </p> </li> <li> <p>KoreaMed (1997 to 18 November 2013) (<a href="./appendices#CD009532-sec-0143">Appendix 10</a>); </p> </li> <li> <p>PakMediNet (1995 to 18 November 2013) (<a href="./appendices#CD009532-sec-0144">Appendix 11</a>); </p> </li> <li> <p>Web of Science Conference Proceedings Citation Index‐Science (CPCI‐S) (1990 to 18 November 2013) (<a href="./appendices#CD009532-sec-0145">Appendix 12</a>). </p> </li> </ul> </p> <p>We searched the following clinical trials registers:</p> <p> <ul id="CD009532-list-0004"> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (18 November 2013); </p> </li> <li> <p>ISRCTN Register (18 November 2013);</p> </li> <li> <p>WHO International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">http://apps.who.int/trialsearch/</a>) (18 November 2013); </p> </li> <li> <p>UMIN‐CTR Japanese Clinical Trials Registry (<a href="http://www.umin.ac.jp/ctr/" target="_blank">http://www.umin.ac.jp/ctr/</a>) (18 November 2013); </p> </li> <li> <p>Hong Kong Clinical Trials Registry (<a href="http://www.hkclinicaltrials.com/" target="_blank">http://www.hkclinicaltrials.com/</a>) (18 November 2013). </p> </li> </ul> </p> <p>Search strategies used to search the registers are listed in <a href="./appendices#CD009532-sec-0146">Appendix 13</a>. </p> <p>In MEDLINE we combined the search strategy with the Cochrane highly sensitive filter for identifying RCTs, as detailed in Chapter 6 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009532-bbs2-0076" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>). We combined searches in EMBASE and CINAHL with adaptations of the relevant SIGN RCT filters (<a href="http://www.sign.ac.uk/methodology/filters.html" target="_blank">http://www.sign.ac.uk/methodology/filters.html</a>). </p> <p>Two of the ongoing trial databases listed in the protocol (the Chinese Clinical Trials Registry and the Sri Lanka Clinical Trials Registry) are now included within the WHO ICTRP database. </p> </section> <section id="CD009532-sec-0032"> <h4 class="title">Searching other resources</h4> <section id="CD009532-sec-0033"> <h5 class="title">Handsearching of reference lists</h5> <p>We checked references of all identified trials, relevant review articles and current treatment guidelines for further literature. These searches were limited to the 'first‐generation' reference lists. </p> </section> </section> </section> <section id="CD009532-sec-0034"> <h3 class="title" id="CD009532-sec-0034">Data collection and analysis</h3> <section id="CD009532-sec-0035"> <h4 class="title">Selection of studies</h4> <p>One review author, Carolyn Doree (CD), initially screened all search hits for relevance against the eligibility criteria and discarded all those that were clearly irrelevant. Thereafter two other authors (GS and SF) independently screened all the remaining hits (titles, abstracts and full text) for relevance against the full eligibility criteria. We retrieved full‐text papers for all those references for which a decision of eligibility could not be made from title and abstract alone. Where possible, we sought further information from the authors where articles contained insufficient data to make a decision about eligibility. We resolved differences of opinion through discussion and consensus, where necessary with reference to a third author, David Roberts (DR). We have detailed studies which did not meet our eligibility criteria in the '<a href="./references#CD009532-sec-0155" title="">Characteristics of excluded studies</a>' table. </p> </section> <section id="CD009532-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (GS and SF) independently extracted data onto customised forms. We piloted these forms with two included RCTs; we made subsequent changes to the data extraction form where appropriate and agreed by both authors. Throughout the data extraction process we resolved any disagreements by consensus. If agreement could not be met, we consulted a third author (DR). The review authors were not blinded to names of authors, institutions, journals or the outcomes of the trials. We translated papers requiring translation into English prior to data extraction. </p> <p>Where data were reported graphically and we considered graphs to be of sufficient quality, two authors (GAS, SAF) estimated values from the graph and used the average value across both estimates. </p> <p>Several studies reported outcomes separately for males and females. In these studies, we combined data for males and females to enable comparisons with other studies. </p> </section> <section id="CD009532-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (GS and SF) independently assessed all included studies for possible risk of bias and made explicit judgements about whether studies were at risk of bias according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009532-bbs2-0075" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We assessed the design, conduct and analysis of the trial using a three‐point scale: low risk of bias, high risk of bias or unclear. To assess risk of bias, the authors included the following questions in the 'Risk of bias' table for each included study: </p> <p> <ul id="CD009532-list-0005"> <li> <p>Was the allocation sequence adequately generated?</p> </li> <li> <p>Was allocation adequately concealed?</p> </li> <li> <p>Was knowledge of the allocated intervention adequately prevented (i.e. blinded) throughout the study? </p> </li> <li> <p>Were incomplete outcome data adequately addressed for every outcome?</p> </li> <li> <p>Were reports of the study free of selective outcome reporting?</p> </li> <li> <p>Was the study apparently free of other problems that could put it at risk of bias?</p> </li> </ul> </p> <p>We explored the impact of the level of bias by undertaking sensitivity analyses (see <a href="#CD009532-sec-0045">Sensitivity analysis</a>). </p> <p>In many of the included studies, reporting of randomisation and blinding methods used was poor. Several studies reported only that the trial was "double‐blind". We interpreted "double‐blind" in the context of iron supplementation trials as an indication that the participants (but not necessarily the outcome assessors) were blinded, and have classified such studies as having a low risk of performance bias. Use of a placebo was not considered sufficient alone to indicate blinding of participants. </p> </section> <section id="CD009532-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>Dichotomous outcomes are presented as risk ratios (RR) with 95% confidence intervals (CI). For continuous outcomes, we recorded the mean and standard deviation. For continuous outcomes measured using the same scale, the effect measure is the mean difference (MD) with 95% CI. </p> </section> <section id="CD009532-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>Within each comparison of interventions of this review, for studies with more than two treatment arms, we avoided multiple pairwise comparisons of treatment groups by pooling treatment groups as appropriate. For dichotomous variables, we summed count data across groups and for continuous variables, we calculated the mean and standard deviation of the combined group from the mean and standard deviations of each subgroup. </p> <p>Thus, for the comparison of iron supplementation versus placebo, we combined multiple iron supplementation trial arms for an overall comparison with the control or placebo arm. Similarly, in the comparison of different iron preparations, we combined different doses of an identical preparation for comparison with an alternative iron preparation. </p> <p>For studies in which results were reported separately for males and females, we combined these data for the main analyses. We converted standard errors, P values and confidence intervals to standard deviations where necessary. We excluded studies in which continuous variables were reported as medians or geometric means without a measure of variation from the analysis. </p> <p>We undertook conversion of units of total iron from µmol/L to µg/dL using 1 µg/dL = 0.179 µmol/L where necessary to allow meta‐analysis across studies reporting outcome values using different units. </p> </section> <section id="CD009532-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>In view of the time that had elapsed since publication of the majority of studies, we made no attempt to contact individual study authors or institutions regarding missing data. We recorded the number of patients lost to follow‐up for each trial as unexplained or analysed undocumented differences between the number of patients randomised and the number of patients, and incorporated this into the assessment of risk of bias. Our preferred analysis was intention‐to‐treat (ITT), but where insufficient data were presented in the included studies, we used per‐protocol analysis. Studies which performed ITT analyses are shown in the <a href="./references#CD009532-sec-0154" title="">Characteristics of included studies</a> tables. </p> </section> <section id="CD009532-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed statistical heterogeneity of treatment effects between trials using Chi<sup>2</sup> tests with a significant level at P &lt; 0.1. We used the I<sup>2</sup> statistic to quantify the amount of possible heterogeneity (where I<sup>2</sup> &gt; 30% denotes moderate heterogeneity and I<sup>2</sup> &gt; 75% denotes considerable heterogeneity). We assessed uncertainty in I<sup>2</sup> values with 95% confidence intervals calculated using the test based method (<a href="./references#CD009532-bbs2-0074" title="HigginsJP , ThompsonS . Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine2002;21:1539–58. ">Higgins 2002</a>). We explored potential causes of heterogeneity by sensitivity and subgroup analyses. </p> <p>We assessed clinical heterogeneity based on individual study characteristics (e.g. by examining differences in study quality, in the donation history and donor characteristics, and in the definition or measurement of outcomes of each study). </p> </section> <section id="CD009532-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>We made every effort to identify unpublished studies through searching of conference abstracts and ongoing trial databases as described in the <a href="#CD009532-sec-0030">Search methods for identification of studies</a>. We intended to assess publication bias using funnel plots but the number of included studies was lower than the minimum suggested for evaluation of funnel plot asymmetry for all outcomes (<a href="./references#CD009532-bbs2-0075" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), therefore formal assessment of publication bias was not possible. </p> </section> <section id="CD009532-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We performed meta‐analyses using Review Manager software (<a href="./references#CD009532-bbs2-0084" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012. ">RevMan 2012</a>). We had intended to carry out meta‐analyses using fixed‐effect models initially. However, in view of the differences in study participants (first‐time donors, repeat donors, deferred donors) in the included studies and the likely heterogeneity between these groups, we used random‐effects models for all meta‐analyses. </p> <p>We assessed the dichotomous outcome of rate of low Hb deferral at the first post‐treatment donation visit as well as after multiple post‐donation visits (i.e. the final visit over study period) and cumulatively over all donation visits during the study period. </p> <p>Few studies reported continuous outcomes as mean change from baseline values and therefore we compared endpoint (follow‐up) values for all comparisons, with the exception of one study (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>), in which no endpoint values were reported. Data from this study were reported graphically with no measures of variation and therefore were not analysed. We assessed continuous outcomes at the first post‐donation visit prior to donation, and after post‐treatment donation or donations. We excluded one study in which measurements were taken at the first post‐treatment visit as it was unclear whether the measurement was taken prior to or after donation (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>). </p> <p>As well as the quantitative synthesis described above, we made an overall interpretation of the data based on a qualitative summary of the included studies. </p> <p>We produced a 'Summary of findings' table using the GRADE profiler, as suggested in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009532-bbs2-0086" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. Wiley ‐ Blackwell, 2008:Chapter 12. ">Schünemann 2011</a>). </p> </section> <section id="CD009532-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We investigated heterogeneity by visual inspection of forest plots and by formal subgroup analyses by sex for the comparison of iron supplementation versus placebo by comparing outcomes between male‐ and female‐specific studies as well as sex‐specific results reported within individual studies. We included one study of predominantly (98.8%) male participants as a male‐specific study in subgroup analyses of sex (<a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). The number of studies for all other comparisons precluded subgroup analysis. </p> </section> <section id="CD009532-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We assessed the robustness of findings for the primary outcome, risk ratio of low Hb deferral and for Hb and serum ferritin levels using sensitivity analysis, including only those trials at low risk of performance bias, and including only those trials in which 25% or less of randomised participants were lost to follow‐up. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009532-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009532-sec-0046"></div> <section id="CD009532-sec-0047"> <h3 class="title">Description of studies</h3> <section id="CD009532-sec-0048"> <h4 class="title">Results of the search</h4> <p>Searches of electronic databases carried out in April 2011 and updated in May 2013 and November 2013 identified a total of 1951 references. Removal of duplicates resulted in 1032 references, which two review authors (GAS, SAF) screened independently in duplicate. We resolved discrepancies through discussion with a third review author (DR). Initial screening of these 1032 references for eligibility against the inclusion criteria excluded a further 964 references. Of the remaining 68 references, we excluded 21 after closer inspection of the full text showed that they did not fully meet the eligibility criteria (as described in the <a href="./references#CD009532-sec-0155" title="">Characteristics of excluded studies</a>). Eight additional references describing seven independent trials met the inclusion criteria but did not report sufficient data for inclusion; details are given in <a href="./references#CD009532-bbs1-0003" title="">Studies awaiting classification</a>). One other reference described a trial protocol (see <a href="./references#CD009532-sec-0157" title="">Characteristics of ongoing studies</a>). Searches of ongoing trial databases resulted in 33 ongoing trials for screening, six of which were unpublished trials relevant to this review and are included as ongoing studies. Study classification is summarised by a PRISMA flow diagram (<a href="#CD009532-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD009532-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram." data-id="CD009532-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> </div> </section> <section id="CD009532-sec-0049"> <h4 class="title">Included studies</h4> <p>A total of 38 references (31 full papers and seven conference abstracts) describing 30 independent trials met the inclusion criteria. In one study, participants were stratified into two subgroups according to serum ferritin levels and each of the two treatments was randomised within both subgroups. For the purposes of this review, we treated these two independent participant subgroups as two separate trials (<a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>). </p> <p>Studies were carried out worldwide, including seven studies from the United States (<a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>), six from Sweden (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>), four from South Africa (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>), three from Germany (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>), three from Switzerland (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), two from Iran (<a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>), two from Norway (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>) and one each from France (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>), Italy (<a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>) and Thailand (<a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>). </p> <p>Seven references describing six independent studies required translation into the English language (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>). </p> <section id="CD009532-sec-0050"> <h5 class="title">Participants</h5> <p>Six studies were of male donors only (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>), and in a further study 98.8% of participants were male (<a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). Eleven studies included only females (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>); eight of these were studies of women who were menstruating or of child‐bearing age (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). Of the remaining 12 studies, five reported results separately for male and female donors (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>), six reported results pooled across male and female donors (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>), and one study did not specify the sex of the participants (<a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>). In studies of male and female donors, the percentage of male participants ranged from 3.1% to 71.2%. </p> <p>With the exception of those studies of women of child‐bearing age, only two studies reported an age restriction on participants, which was from 18 to 56 years (<a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>), and from 18 to 25 years (<a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>). Participants in a third study were exclusively military service recruits (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>). </p> <p>Studies included both regular/repeat and first‐time donors. Thirteen studies recruited regular donors, defined as having donated at least five donations in the previous two years (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>), at least four donations (<a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>), or two donations (<a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>) in the past year, with a median of three (range 0 to 21) previous donations over their lifetime (<a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>), or with an undefined donation history (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>; <a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). Donors in six studies had made at least one previous donation (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a><a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>), or included a majority (89%) of repeat donors (<a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). Only two studies recruited participants with no previous history of donation (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>); the donation history was unknown in two studies (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>). Five studies were of deferred donors with Hb &lt; 130 g/L (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>), haematocrit &lt; 35% (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>), low haematocrit (<a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), or failing a copper sulphate test at enrolment (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>), or donors deferred at their previous visit (<a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>). </p> </section> <section id="CD009532-sec-0051"> <h5 class="title">Interventions</h5> <p>Nineteen studies included two trial arms, which included comparisons of iron supplementation versus placebo (<a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), or no iron supplementation (<a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>; <a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>), oral versus parenteral iron supplementation (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>), different doses of the same iron preparation (<a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>), and different preparations of iron supplementation (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>). </p> <p>In one report, participants were stratified according to serum ferritin levels and two independent trials were carried out, comparing iron supplementation with placebo (<a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>). </p> <p>Seven studies involved three trial arms, of two different iron preparations versus a placebo (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>), two different doses of iron supplementation versus placebo (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>), iron supplementation and/or vitamin C (<a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>), and iron supplementation versus two doses of an alternative iron preparation (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>). </p> <p>One four‐arm study compared different durations of iron supplementation or placebo, administered in vials, with iron supplementation administered in sachets at the full dose or replaced with placebo for the latter part of the trial (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>); a second four‐arm study compared iron supplementation with two different levels of glycerophosphate and with an alternative iron preparation (<a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>). </p> <p>From these studies, we were able to include 19 comparisons of iron supplementation and placebo or control; one comparison of oral and parenteral iron supplementation; four comparisons of different doses of iron supplementation; one comparison of different durations of iron supplementation; and 12 comparisons of different iron preparations. </p> <p>Iron preparations included carbonyl or elemental iron, ferrous compounds (ferrous sulphate, ferrous carbonate, ferrous gluconate, ferrous glycine, ferrous fumarate, ferrous sulphate heptahydrate) and ferric compounds (ferric polymaltose, ferric protein succinylate, ferric sucrose, ferric glycerophosphate). The dose and duration of iron supplementation varied greatly across studies; from 50 mg ferrous sulphate three times daily for seven days, to 100 mg ferrous carbonate daily for one year (<a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>). Four studies described iron preparations which included vitamin C (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). Full details of the interventions in each trial are given in <a href="#CD009532-tbl-0002">Table 1</a>. </p> <div class="table" id="CD009532-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study<sup>a</sup> </b> </p> <p><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention<sup>b</sup> (elemental iron dose)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Reported outcomes<sup>c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow‐up time points<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Description of study participants</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Duraferon) (100 mg daily for 20 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, RLS, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Week 4 and week 8 (non‐donation); donation 2 to 4 (♀) or  2 to 5 (♂); last donation is ≥ 1 year post‐1<sup>st</sup> donation </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Experienced donors having given at least 5 donations in last 1 to 2 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup>sucrose (Venofer) (1 x 200 mg given intravenously) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> + Vit C (Ferro‐Grad Abbott) (105 mg (+ 500 mg Vit C) daily for "following months") </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, MCV, SeFe, TIBC, AE, SI, Sat</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>At second donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate + Vit C (Collett Iron) (20 mg (+ 120 mg Vit C) daily, treatment duration unclear) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, transferrin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 months after baseline measures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female blood donors with depleted iron stores (serum ferritin &lt; 20 μg/L and haemoglobin &gt; 120 g/L) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Vitalia Hemojern) (16 mg (+ 2 mg heme iron from porcine blood) daily, treatment duration unclear) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (100 mg daily for 56 days) with scheduled visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean no. donations per year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 30 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Females pledged to donate four times each year.</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (scheduled visits only)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Resoferon) (37 mg 3 times daily for 28 days (one vial)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low Hb deferral, Hb, Hct, MCHC, transferrin, AE, PI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Day 14 and day 28 post‐donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Healthy blood donors blood group B; haemoglobin 125 to 135 g/L</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Resoferon) (37 mg 3 times daily for 28 days (28 sachets)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Resoferon) (37 mg 3 times daily for 4 days (4 sachets) followed by placebo for 24 days (24 sachets)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (3 times daily for 28 days (1 vial))</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Eryfer) (50 mg (+ 222 mg Vit C + 84 mg NaHCO<sub>3</sub>) twice daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>After 30 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Blood donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (alternative) (50 mg (+ 222 mg Vit C) twice daily for 30 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (273.8 mg maize starch + 1.2 mg Aerosil twice daily for 30 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Tardyferon) (80 mg (+ 80 mg muco‐protein) daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, Hct, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 2 after end of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Deferred donors with Hb &lt; 130 g/L  (Hct &lt; 37%) and no history of medical pathology for anaemia </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (66 mg twice daily for 18 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> gluconate (Fergon) (37.5 mg twice daily for trial duration) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, SeFe, transferrin, ZP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ 8 weeks since previous donation or 4 weeks since deferral, for 5 visits including initial visit </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female donors failing previous Hb screen (some were eligible to donate at start of study) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (calcium phosphate twice daily) for trial duration</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (100 mg daily for 84 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, MCV, SeFe, transferrin, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weeks 0, 1, 3, 6, 12, 16 (none were donation visits)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Menstruating, non‐pregnant women 18 to 40 years old recently deferred from donation (Hct &lt; 35%) with an absence of known medical disorders and no iron supplementation since deferral from blood donation and a MCV &lt; 85 fL and ferritin &lt; 12 μg/L </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (100 mg daily for 84 days) </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>* (Adolfsson 1968*; </p> <p>Lieden</p> <p>1975)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> succinate (Ferromyn S) (74 mg (+220 mg succinic acid) twice daily for 2 weeks) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hb, Hct, TIBC, PA, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 months after 6 subsequent donations (inter‐donation interval 2 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Young, healthy, male conscripts with no past history of haematological, gastrointestinal or renal disorder. None had previous haemorrhage or had served as blood donors </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> succinate (Ferromyn S) (34 mg (+110 mg succinic acid) twice daily for 2 weeks) </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 2 weeks)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Hemofer) (8 mg (+1.2 mg heme iron from porcine blood) twice daily for first month then second or third month) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular blood donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Erco‐Fer) (60 mg daily for first month then second or third month) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (600 mg 3 times daily for 7 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hb, MCV, SeFe, TIBC, AE, SI, Sat,  FEP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Day 56 after successful donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Previous (at least once) female donors  of child‐bearing age who were not pregnant and came to donate blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (60 mg 3 times daily for 7 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (3 times daily for 7 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (600 mg 3 times daily for 21 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, MCV, SeFe, TIBC, AE, SI, Sat,  FEP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weeks 1, 3, 6, 12, 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female blood donors of child‐bearing age who were not pregnant recently deferred from repeat donation due to low Hct </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (60 mg 3 times daily for 21 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (100 mg daily for 56 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, MCV, SeFe, transferrin, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 56 after successful donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Repeat female donors  of child‐bearing age who were not pregnant and came to donate blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (60 mg twice daily for 84 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Low Hb deferral, Hb, SeFe, NIA, AE, SI, Sat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Weeks 1, 2, 4, 8, 12. Not donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Donors failing CuSO4 Hb screening test, i.e. deferred donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg (+3.6 mMol/L GlyP) twice daily for 84 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hb, SeFe, transferrin, AE, SI, RCF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Weeks 4, 8 and 12. Not donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Regular donors failing CuSO4 Hb screening test</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg (+1.9 mMol/L GlyP) twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> ("equivalent dose" twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> protein succinylate (Legofer) (80 mg daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, Hct, MCV, MCH, MCHC, SeFe, transferrin, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>End of trial: mean 30 +/‐ 2.2 days (range 23 to 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood donors aged 18 to 56 with low levels of stored iron (serum ferritin &lt; 30 ng/100 mL) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (105 mg daily for 30 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> carbonate (100 mg daily for 1 year) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, TIBC, NIA, AE, SI, PCV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 4th and 6th donations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Young, male, first‐time donor conscripts with no history of bleeding</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup>carbonate (20 mg daily for 1 year) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (ACO) (100 mg daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 1st, 2nd and 3rd  donations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Previous donors (all except 14/500) without iron deficiency anaemia during the most recent years, could tolerate different iron preparations and intended to continue to give blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Erco‐Fer) (60 mg daily for 30 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Elemental"” iron (56 mg daily for 90 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, Hct, SeFe, transferrin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After ˜3 months (assumed no donations)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Male volunteer and paid blood donors who had previously donated</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 90 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (Ferrimed DS) (100 mg twice daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 56 days of treatment (not donation visit)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular donors (at least 4 donations in previous year) passing the Hb test and with low serum ferritin (less than 20 μg/L) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (Ferrimed DS) (100 mg twice daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 56 days of treatment (not donation visit)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular donors (at least 4 donations in previous year) passing the Hb test and with high serum ferritin (between 50 and 150 μg/L) </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (150 mg 3 times daily for 7 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, Hct, SeFe, TIBC, AE, SI, Sat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Visits 1 (4 months), 2 (8 months) and 3 (12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female, successful blood donors &lt; 45 years who were not pregnant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (3 times daily for 7 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (50 mg daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 7, 28 and 56. Not donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular (at least 2 donations in past year) healthy female donors of childbearing age. 72% had previously been taking iron supplements </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> gluconate (20 mg (+ 400 mg Vit C) twice daily for 6 months) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Low Hb deferral, SeFe, transferrin, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>♂ = 2/4/6 months; ♀ = 3/6 months. All were donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Regular, healthy donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> gluconate (+ 400 mg Vit C) (10 mg twice daily for 6 months) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (+400 mg Vit C) (twice daily for 6 months)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> Glycine SO<sub>4</sub> (ferro sanol duodenal) (100 mg daily for 8 to 10 weeks) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Before donation visits 1, 2, 3 Inter‐donation interval 8 to 10 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular, healthy donors with a minimum body weight of 68 kg and Hb of 145 g/L giving 2‐unit RBC by apheresis </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 8 to 10 weeks)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> Glycine SO<sub>4</sub> (Niferex©) (100 mg daily for 8 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, transferrin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 8 (+/‐ 2) after initial donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Donors with at least 1 prior donation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (100 mg twice daily for 14 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Day 14 post‐donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Regular blood donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> heptahydrate (100 mg twice daily for 14 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 14 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub>  (37 mg daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hb, SeFe, TIBC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Donation visits 2, 3, 4, 5 etc. (inter‐donation interval 8 to 12 weeks, mean 9.5 weeks) with at least 4 donation visits </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Regular, female blood donors committing to donate blood every 8 weeks for 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub>  (37 mg (+75 mg Vit C) daily for 56 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(100 mg Vit C daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Tardyferon) (80 mg daily for 28 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, Cog, PA, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 week after donation (randomisation) and 4 weeks post‐randomisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Successful female blood donors (non‐anaemic but iron‐deficient after donation)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 28 days)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>* = translated. </p> <p><sup>b</sup>Fe<sup>2+</sup> SO<sub>4</sub> = iron (II) sulphate; Fe<sup>3+</sup>sucrose = iron (III) sucrose; Fe<sup>2+</sup> = ferrous (II) salt; Fe<sup>3+</sup> = ferric (III) salt; NaHCO<sub>3</sub> = sodium bicarbonate; Vit C = vitamin C; GlyP = glycerophosphate. All treatments were administered orally with the exception of ferric sucrose, given intravenously in <a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>.  </p> <p><sup>c</sup>AE = adverse effects; Cog = cognitive function; FEP = free erythrocyte protoporphyrin; Hb = haemoglobin; Hct = haematocrit; MCH = mean cell Hb; MCHC = MCH concentration; MCV = mean cell volume; NIA = net iron absorption; PA = physical activity; PI = plasma iron; RLS = restless legs syndrome; Sat = percentage saturation; SeFe =serum ferritin; SI = serum iron; TIBC = total iron binding concentration; ZP = zinc protoporphyrin </p> <p><sup>d</sup>♂ = males, ♀ = females. </p> </div> </div> </section> <section id="CD009532-sec-0052"> <h5 class="title">Outcomes</h5> <p>The duration of follow‐up varied greatly between studies. Ten studies reported outcomes after up to five donations subsequent to the administration of iron supplementation (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). In two studies, it was unclear whether any donations following treatment had taken place at the time of follow‐up (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>). Eighteen studies measured outcomes before any further donations. Time points ranged from a mean of eight days (<a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>) to 16 weeks (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), with a median follow‐up time before further donation of 56 days. </p> <p>The primary outcome of this review, risk ratio of low Hb deferral, was reported in only eight studies (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). Haemoglobin and serum ferritin levels were widely reported; other reported blood indices included mean cell/corpuscular volume (MCV), serum or plasma iron, total iron binding capacity (TIBC) and transferrin saturation. Health‐related quality of life measures were poorly reported; only two studies included measures of physical activity and fatigue (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), and no studies reported measures of mood disturbance or cognitive function. The majority of studies described adverse effects. Reported outcomes (including those not considered in this review) and endpoints in individual studies are shown in <a href="#CD009532-tbl-0002">Table 1</a>. </p> </section> </section> <section id="CD009532-sec-0053"> <h4 class="title">Excluded studies</h4> <p>We excluded 20 studies described in 21 references from the review following full‐text assessment against the eligibility criteria (see <a href="./references#CD009532-sec-0155" title="">Characteristics of excluded studies</a>). In summary, three studies included a single treatment arm, two studies allocated treatment without randomisation, in two studies randomisation of treatment could not be confirmed, three studies were of short‐term iron absorption levels, one study randomised vitamin C dose with all participants receiving identical iron supplementation, two observational studies included no iron supplementation, two studies were of non‐donors, one study was of plasmapheresis donors, one study reported results for both blood donors and non‐donors combined, one study was a commentary on iron deficiency in blood donors, one study administered erythropoietin to autologous blood donors and one study was no longer available in print. </p> </section> </section> <section id="CD009532-sec-0054"> <h3 class="title">Risk of bias in included studies</h3> <p>Two review authors independently assessed risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009532-bbs2-0075" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Disagreements were restricted to where one review author deemed risk of bias as unclear rather than high or low and were mainly concerned with the interpretation of "double‐blind" (see <a href="#CD009532-sec-0037">Assessment of risk of bias in included studies</a>). We resolved all disagreements by discussion and with further reference to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009532-bbs2-0075" title="Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>Overall, the risk of bias varied from low to high, with the majority of studies being unclear as to their quality (see <a href="./references#CD009532-sec-0154" title="">Characteristics of included studies</a>). This was mainly due to the age of the studies, with more recent studies using more rigorous methodologies. A summary of the risk of bias is shown in <a href="#CD009532-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD009532-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009532-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD009532-sec-0055"> <h4 class="title">Allocation</h4> <p>Of the 30 included studies, we assessed only seven as having a low likelihood of selection bias (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). In these studies, treatment allocation was randomised using web‐based systems, computer‐generated charts (n = 2), random block design (n = 3) and participant choice of randomised cards in envelopes. The risk of selection bias in 23 studies was unclear as none reported their method of randomisation. </p> <p>No method for concealment of allocation was reported in 23 studies. In seven studies, two did not conceal allocation (<a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>: <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>), and one used computer‐generated charts (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>); we assessed these as having a high risk of selection bias. We assessed four studies as being of low risk due to the use of code‐marked prescriptions (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). </p> </section> <section id="CD009532-sec-0056"> <h4 class="title">Blinding</h4> <p>There was no blinding of participants in six of the studies so we considered these to have a high risk of performance bias (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>). Eleven studies gave no indication of participant blinding so we recorded them as having an unclear risk. Of the 13 studies assessed as low risk, nine stated the studies as being double‐blind, either with the use of a placebo (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>), or assumed to include participant blinding without explicitly stating so (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>); four used coded bottles for the prescriptions (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). </p> <p>Only three of the 30 studies described any blinding of the outcome assessment and we rated them as low risk (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>: <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>); we classified the remainder as unclear risk. </p> </section> <section id="CD009532-sec-0057"> <h4 class="title">Incomplete outcome data</h4> <p>We investigated the completeness of data and have described the reasons for attrition or exclusion where reported for each included study and whether missing data were balanced across groups. We rated 10 studies as being low risk (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), two were of unclear risk (<a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>; <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>), and the remainder had high risk of attrition bias, with a difference in missing data of greater than 5% between treatment arms, a high rate of loss to follow‐up or, in one case, because the number of participants randomised to each arm was not reported (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>). </p> </section> <section id="CD009532-sec-0058"> <h4 class="title">Selective reporting</h4> <p>All of the pre‐specified outcomes published in the protocol for the <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a> study were reported, and we deemed this study to have a low risk of bias. A high risk of bias was associated with one study, in which the authors failed to report three pre‐specified outcomes of interest (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>). In all 29 remaining studies, where all outcomes listed in the manuscript were reported but no study protocol was available to determine the full list of pre‐specified outcomes, the risk of reporting bias was unclear. No unpublished data were received, so there is currently no additional evidence of reporting bias. </p> </section> <section id="CD009532-sec-0059"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed each included study for other factors that might contribute to additional risk of bias. We have noted any concerns we had about other possible sources of bias and rated them thus: </p> <p> <ul id="CD009532-list-0006"> <li> <p>high risk of further bias ‐ where the manufacturer has provided support, in terms of a grant (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>), and additional help (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>: <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>: <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>), or where the manufacturer supplied some co‐authors (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>); </p> </li> <li> <p>unclear ‐ where the risk of further bias is uncertain, most commonly where a study has been supplied with iron supplements and/or placebo by a particular manufacturer (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>), or there were limited data available from a conference abstract (<a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>); </p> </li> <li> <p>low risk of further bias ‐ where there was explicit declaration of independence from study sponsors (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), or where no other sources of bias could be identified (18 studies). </p> </li> </ul> </p> </section> </section> <section id="CD009532-sec-0060"> <h3 class="title" id="CD009532-sec-0060">Effects of interventions</h3> <p>See: <a href="./full#CD009532-tbl-0001"><b>Summary of findings for the main comparison</b> Iron supplementation for iron deficiency and/or anaemia in blood donors</a> </p> <section id="CD009532-sec-0061"> <h4 class="title">A. Iron supplementation versus placebo/control</h4> <p>Nineteen studies compared iron supplementation with placebo or control (see <a href="#CD009532-tbl-0002">Table 1</a>). Haemoglobin, serum ferritin and total iron binding capacity (TIBC) were reported graphically in one study (<a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>); we estimated data for this study from the graphs as described in the <a href="#CD009532-sec-0022">Methods</a> section. </p> <section id="CD009532-sec-0062"> <h5 class="title">(1) Risk ratio of low Hb deferral (primary outcome)</h5> <p>Four studies reported low haemoglobin deferral rates (<a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). One other study reported the mean number of donations per donor per year (<a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a>). At the first donation visit after commencement of treatment, all four studies reported a lower rate of Hb deferral in donors who received iron supplementation than in those who had not, with three studies reporting a significant difference between treatment arms (<a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). Combined evidence from all four studies showed a significantly reduced risk of deferral due to low Hb at the first donation visit after treatment in donors who received iron supplementation (risk ratio (RR) 0.34; 95% confidence interval (CI) 0.21 to 0.55; four studies; 1194 participants; P value &lt; 0.0001) (<a href="./references#CD009532-fig-0003" title="">Analysis 1.1</a>). There was no evidence of heterogeneity between studies (I<sup>2</sup> = 0%; 95% CI 0% to 79.3%). This low Hb deferral risk reduction was maintained after multiple donation visits reported in three studies (RR 0.25; 95% CI 0.15 to 0.41; three studies; 793 participants; P value &lt; 0.00001) (<a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>), and over cumulative donation visits (RR 0.31; 95% CI 0.18 to 0.52; four studies; 2740 participants; P value &lt; 0.00001) (<a href="./references#CD009532-fig-0003" title="">Analysis 1.1</a>). </p> <p>Subgroup analyses revealed no significant differences between male and female donors in low Hb deferral rates at first donation (P value = 0.90) (<a href="./references#CD009532-fig-0045" title="">Analysis 10.1</a>), after multiple donation visits (P value = 0.81) (<a href="./references#CD009532-fig-0046" title="">Analysis 10.2</a>) or over cumulative donation visits (P value = 0.85) (<a href="./references#CD009532-fig-0047" title="">Analysis 10.3</a>), although the number of studies provided low power to detect a difference between subgroups. Results were robust to performance bias (<a href="./references#CD009532-fig-0051" title="">Analysis 11.1</a>) and attrition bias (<a href="./references#CD009532-fig-0054" title="">Analysis 12.1</a>). </p> </section> <section id="CD009532-sec-0063"> <h5 class="title">(2) Hb levels, mean cell volume (MCV), other blood indices and iron stores</h5> <section id="CD009532-sec-0064"> <h6 class="title">i. Haemoglobin (Hb)</h6> <p>Mean Hb levels were reported in 12 studies (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), although in one study results were reported graphically and data extraction could not be undertaken (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>); this study reported no significant differences between treatment groups. </p> <p>In eight studies which reported Hb levels at follow‐up prior to further donation (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), meta‐analysis showed that iron supplementation resulted in significantly higher levels of Hb at follow‐up (mean difference (MD) 2.36 g/L; 95% CI 0.06 to 4.66; eight studies; 847 participants, P value = 0.04), showing a beneficial effect of iron supplementation. A moderate level of heterogeneity was observed between studies (I<sup>2</sup> = 69%; 95% CI 34.3% to 85.1%) (<a href="./references#CD009532-fig-0004" title="">Analysis 1.2</a>). </p> <p>Sensitivity analyses showed that the effect of iron supplementation on Hb levels before further donation remained significant when five studies with a high or unclear risk of performance bias were excluded (MD 4.76 g/L; 95% CI 1.07 to 8.45; three studies; 270 participants; P value = 0.01) (<a href="./references#CD009532-fig-0052" title="">Analysis 11.2</a>), and when studies with less than 75% of randomised participants included in the analysis were excluded (MD 2.90 g/L; 95% CI 0.23 to 5.57; six studies; 698 participants; P value = 0.03) (<a href="./references#CD009532-fig-0055" title="">Analysis 12.2</a>). </p> <p>Subgroup analysis by sex revealed that the difference in Hb level between treatment arms was found in female donors (MD 3.56 g/L; 95% CI 0.21 to 6.92; four studies; 431 participants; P value = 0.04), but not male donors (MD 0.08 g/L; 95% CI ‐1.90 to 2.05; four studies; 297 participants; P value = 0.94). A test for subgroup differences was not significant (P value = 0.08) (<a href="./references#CD009532-fig-0048" title="">Analysis 10.4</a>), although the number of studies provided low power to detect a difference between subgroups. We observed no heterogeneity across four studies reporting Hb levels in males (I<sup>2</sup> = 0%; 95% CI 0% to 32.8%); however, four studies reporting Hb levels in females showed high heterogeneity (I<sup>2</sup> = 80%; 95% CI 48.3% to 92.6%), with no clear differences apparent between these studies. </p> <p>Hb after subsequent donation(s) was reported in three studies (<a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). We found a significant difference in Hb levels between treatment arms in favour of iron supplementation after donation (MD 6.37 g/L; 95% CI 2.36 to 10.39; three studies; 406 participants; P value = 0.002) (<a href="./references#CD009532-fig-0004" title="">Analysis 1.2</a>), with high heterogeneity across studies (I<sup>2</sup> = 84%; 95% CI 50.9% to 94.6%). Visual inspection of the forest plot showed a particularly strong effect from one study of menstruating female blood donors with an inter‐donation interval of between eight and 12 weeks (<a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). There was no residual evidence for heterogeneity when this study was excluded (I<sup>2</sup> = 0%). </p> </section> <section id="CD009532-sec-0065"> <h6 class="title">ii. Mean corpuscular volume (MCV)</h6> <p>Two studies reported MCV before further donation; both studies reported higher mean MCV levels at follow‐up in donors who received iron supplementation compared with those who did not (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>). However, meta‐analyses of these two studies did not provide evidence for a difference in MCV between treatment arms (MD 1.37 fL; 95% CI ‐0.17 to 2.92; two studies; 127 participants; P value = 0.08) (<a href="./references#CD009532-fig-0005" title="">Analysis 1.3</a>). </p> </section> <section id="CD009532-sec-0066"> <h6 class="title">iii. Serum ferritin</h6> <p>Serum ferritin (ng/mL) before further donation was reported as an outcome in nine studies (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). However, three studies reported serum ferritin as geometric mean (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>), and a fourth study reported median serum ferritin values, with no suitable measure of variation for inclusion of the data from these studies in a quantitative synthesis (<a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>). In these four studies, one reported a significant difference in serum ferritin between treatment arms in favour of iron supplementation (<a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>); two reported significant increases in serum ferritin from baseline in the iron supplementation group but not the placebo/control group (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>), and one reported no difference in serum ferritin between treatment groups (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>). </p> <p>In five studies, we found significantly higher mean serum ferritin levels at follow‐up in donors who received iron supplementation compared with those who did not in all but one study (<a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>), in which donors were pre‐selected for high serum ferritin (between 50 and 150 ng/mL). Meta‐analysis of all five studies showed that iron supplementation resulted in significantly higher levels of serum ferritin (MD 13.98 ng/mL; 95% CI 8.92 to 19.03; five studies; 640 participants; P value &lt; 0.00001). We found a moderate level of heterogeneity (I<sup>2</sup> = 68%; 95% CI 16.0% to 87.5%) between studies (<a href="./references#CD009532-fig-0006" title="">Analysis 1.4</a>). The effect remained significant when we excluded the study with high baseline serum ferritin levels (MD 13.67 ng/mL; 95% CI 8.39 to 18.95; four studies; 617 participants; P value &lt; 0.00001). </p> <p>Subgroup analysis showed that the significant improvement in serum ferritin associated with iron supplementation was found in both male and female donors (males: MD 10.94 ng/mL; 95% CI 1.00 to 20.88; three studies; 265 participants; P value = 0.03; females: MD 14.39 ng/mL; 95% CI 9.90 to 18.88; three studies; 375 participants; P value &lt; 0.00001; test for subgroup differences: P value = 0.53) (<a href="./references#CD009532-fig-0049" title="">Analysis 10.5</a>). </p> <p>Sensitivity analyses showed that the increase in serum ferritin levels associated with iron supplementation before further donation remained significant when we excluded two studies with an unclear risk of performance bias in a sensitivity analysis (MD 13.31 ng/mL; 95% CI 7.22 to 19.40; three studies; 594 participants; P value &lt; 0.0001) (<a href="./references#CD009532-fig-0053" title="">Analysis 11.3</a>) and when studies with less than 75% of randomised participants included in the analysis were excluded (MD 15.24 ng/mL; 95% CI 12.37 to 18.11; three studies; 189 participants; P value &lt; 0.00001) (<a href="./references#CD009532-fig-0056" title="">Analysis 12.3</a>). </p> <p>Mean serum ferritin levels after subsequent donation(s) were reported in three trials (<a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>). One other study reported serum ferritin levels graphically as geometric mean values (<a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). Meta‐analysis of the three trials reporting mean values showed that the significant difference in mean serum ferritin in favour of iron supplementation was maintained after subsequent donation(s) (MD 9.01 ng/mL; 95% CI 5.76 to 12.25; three studies; 619 participants; P value &lt; 0.00001), with no evidence for heterogeneity across studies (I<sup>2</sup> = 0%; 95% CI 0% to 86.7%) (<a href="./references#CD009532-fig-0006" title="">Analysis 1.4</a>). </p> </section> <section id="CD009532-sec-0067"> <h6 class="title">iv. Serum or plasma iron</h6> <p>Serum or plasma iron concentration was reported in five studies (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>), although in one study results were reported graphically and data extraction could not be undertaken (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>); no significant differences between treatment groups were reported in this study. In three studies which reported serum or plasma iron concentration before further donation (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>), meta‐analysis showed no evidence for a difference between treatment arms (MD 11.76 μg/dL; 95% CI ‐1.67 to 25.20; three studies; 246 participants; P value = 0.09), with moderate heterogeneity across studies (I<sup>2</sup> = 59%; 95% CI 0% to 88.4%). Only one study reported serum or plasma iron concentration after post‐treatment donation(s); this study found significantly higher levels of serum iron in donors who received iron supplementation (MD 7.89 μg/dL; 95% CI 1.12 to 14.66; 252 participants; P value = 0.02) (<a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>) (<a href="./references#CD009532-fig-0007" title="">Analysis 1.5</a>). </p> </section> <section id="CD009532-sec-0068"> <h6 class="title">v. Total iron binding capacity (TIBC)</h6> <p>TIBC was reported in five studies (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>), although in one study results were reported graphically and data extraction could not be undertaken (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>); this study reported no significant differences between treatment groups. Two studies reported TIBC before further donation (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>), and two studies reported values after subsequent donation(s) (<a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a>). Iron supplementation resulted in significantly lower levels of TIBC consistent with a beneficial effect of iron supplementation both before further donation (MD ‐32.05 μg/dL; 95% CI ‐61.45 to ‐2.65; two studies; 127 participants; P value = 0.03) and after subsequent donations (MD ‐42.64 μg/dL; 95% CI ‐56.99 to ‐28.28; two studies; 315 participants; P value &lt; 0.00001), with low to moderate heterogeneity across studies (I<sup>2</sup> = 43%; I<sup>2</sup> = 29% respectively) (<a href="./references#CD009532-fig-0008" title="">Analysis 1.6</a>). </p> </section> <section id="CD009532-sec-0069"> <h6 class="title">vi. Transferrin saturation (%)</h6> <p>Transferrin saturation (also described as saturation of TIBC) was reported in four studies (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a>). Meta‐analysis of these four studies showed that iron supplementation resulted in significantly higher transferrin saturation levels (MD 3.91%; 95% CI 2.02 to 5.80; four studies; 344 participants; P value &lt; 0.0001), with no evidence for heterogeneity across studies (I<sup>2</sup> = 0%; 95% CI 0% to 60.9%) (<a href="./references#CD009532-fig-0009" title="">Analysis 1.7</a>). Evidence from two studies showed that an increase in transferrin saturation in iron‐supplemented donors compared with placebo was maintained after subsequent donations (MD 4.84%; 95% CI 2.78 to 6.90; two studies; 343 participants; P value &lt; 0.00001) (<a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>) (<a href="./references#CD009532-fig-0009" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD009532-sec-0070"> <h5 class="title">(3) Health‐related quality of life and physical activity</h5> <p>One study reported health‐related quality of life as an outcome, which was assessed by fatigue (level of fatigue on a visual analogue scale and a subjective fatigue severity scale), quality of life (SF‐12V2 self questionnaire: vitality, physical and mental condition) and aerobic capacity (Chester step test) (<a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). In this study, there were no differences in health‐related quality of life measures after four weeks of treatment in any of the measures used, with the exception of physical condition (MD 2.40; 95% CI 0.93 to 3.87; one study; 133 participants; P value = 0.001) (<a href="./references#CD009532-fig-0010" title="">Analysis 1.8</a>). </p> <p>In one other study which reported physical capacity using a bike test, no standard deviations were provided and therefore a formal assessment of the results from this study was not possible (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>). No significant differences between treatment groups were reported. </p> </section> <section id="CD009532-sec-0071"> <h5 class="title">(4) Adverse effects</h5> <p>Fourteen studies reported adverse effects as an outcome although two studies reported adverse effects in the treatment group only (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>), and five studies did not report adverse effects separately for each treatment arm (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>; <a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a>; <a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). Reported adverse effects included constipation, diarrhoea, nausea, vomiting, gastric discomfort, abdominal cramps, headache, dizziness and taste disturbances. Four studies reported the occurrence of cumulative adverse events (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). Meta‐analysis of these four studies showed a significant increased risk of adverse effects associated with iron supplementation (RR 1.60; 95% CI 1.23 to 2.07; four studies; 1748 participants; P value = 0.0005) (<a href="./references#CD009532-fig-0011" title="">Analysis 1.9</a>). </p> <p>Meta‐analysis of studies reporting specific adverse effects showed that iron supplementation was associated with an increased risk of constipation (RR 1.63; 95% CI 1.16 to 2.31; five studies; 1849 participants; P value = 0.005), diarrhoea (RR 2.17; 95% CI 1.38 to 3.42; five studies; 1555 participants; P value = 0.0008), nausea/vomiting (RR 1.75; 95% CI 1.20 to 2.56; six studies; 1922 participants; P value = 0.004) and taste disturbances (RR 5.78; 95% CI 2.10 to 15.95; two studies; 171 participants; P value = 0.0007), whilst there was insufficient evidence for an increased risk of abdominal pain and/or cramps (RR 2.21; 95% CI 0.95 to 5.16; four studies; 683 participants; P value = 0.07), gastric/epigastric pain (RR 1.26; 95% CI 0.73 to 2.19; two studies; 1242 participants; P value = 0.41) or headache (RR 0.91; 95% CI 0.53 to 1.56; five studies; 681 participants; P value = 0.72) (<a href="./references#CD009532-fig-0011" title="">Analysis 1.9</a>). </p> </section> <section id="CD009532-sec-0072"> <h5 class="title">(5) Compliance</h5> <p>Three studies reported compliance as continuation of treatment (iron supplementation or placebo) (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>). Meta‐analysis showed a high risk of discontinuation of treatment in participants who received iron supplementation compared with those who received placebo, although this difference failed to meet statistical significance (RR 0.83; 95% CI 0.68 to 1.01; three studies; 1336 participants; P value = 0.06) (<a href="./references#CD009532-fig-0012" title="">Analysis 1.10</a>). </p> <p>Five studies reported the number of individuals who achieved a high compliance rate, defined as 100% compliance (<a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>), or over 90% compliance (<a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>); however only two trials reported compliance rates separately for both treatment groups (<a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>). Meta‐analysis of these two trials showed no evidence for a difference in compliance rates between treatment groups (RR 0.76; 95% CI 0.51 to 1.15; two studies; 146 participants; P value = 0.19) (<a href="./references#CD009532-fig-0012" title="">Analysis 1.10</a>). Compliance (ingestion of over 90% of tablets) was poor in one‐third of men and one‐quarter of women in one study (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>); a second study by the same authors reported that compliance was "largely similar in both groups" (<a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). One study reported that full compliance was achieved in 92.8% of participants who received iron supplementation (<a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a>). In the <a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a> study, iron supplementation was "well adhered to" in 81.8% of patients although no definition of compliance was given. </p> <p>One study reported the number of days over a total treatment period of 28 days on which tablets were taken (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>); tablets were taken for between 87.7% and 93.4% of total treatment days in participants who received iron supplementation compared with 88.2% in the placebo group. One study reported a mean of 1.6 (standard deviation (SD) 0.4) tablets per day were taken in the iron supplementation group compared with 1.5 (SD 0.7) in the placebo group (<a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>). A compliance rate of 96% was reported in the <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a> study, with similar adherence in both groups. In the <a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a> study, no more than 10 tablets were forgotten by any participant over the entire study period. </p> <p>Seven studies identified reasons for non‐compliance or discontinuation of treatment associated with adverse effects (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>). </p> </section> </section> <section id="CD009532-sec-0073"> <h4 class="title">B. Iron supplementation: oral versus parenteral iron supplementation</h4> <p>One study compared oral and parenteral iron supplementation (<a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>). </p> <section id="CD009532-sec-0074"> <h5 class="title">(1) Risk ratio of low Hb deferral (primary outcome)</h5> <p>Low Hb deferral was not reported in this study.</p> </section> <section id="CD009532-sec-0075"> <h5 class="title">(2) Hb levels, MCV, other blood indices and iron stores</h5> <section id="CD009532-sec-0076"> <h6 class="title">i. Haemoglobin (Hb)</h6> <p>Hb was reported as an outcome in this study, although results were given descriptively, whereby "no significant differences in Hb between the treatment groups were seen". </p> </section> <section id="CD009532-sec-0077"> <h6 class="title">ii. Mean corpuscular volume (MCV)</h6> <p>MCV was not reported in this study.</p> </section> <section id="CD009532-sec-0078"> <h6 class="title">iii. Serum ferritin</h6> <p>Mean serum ferritin was reported both before further donation and after four (women) or five (men) subsequent donations. There was no difference in post‐treatment serum ferritin levels at follow‐up prior to further donation between treatment arms (MD 2.10 ng/mL; 95% CI ‐5.91 to 10.11; 120 participants; P value = 0.61) (<a href="./references#CD009532-fig-0013" title="">Analysis 2.1</a>). However, after further multiple donations, the mean serum ferritin level was significantly higher in donors who received iron supplementation intravenously in a single dose after each donation, compared with those who were administered oral iron supplements (MD 7.65 ng/mL; 95% CI 0.36 to 14.94; 120 participants; P value = 0.04) (<a href="./references#CD009532-fig-0013" title="">Analysis 2.1</a>). </p> </section> <section id="CD009532-sec-0079"> <h6 class="title">iv. Serum or plasma iron</h6> <p>Serum or plasma iron levels were not reported in this study.</p> </section> <section id="CD009532-sec-0080"> <h6 class="title">v. Total iron binding capacity (TIBC)</h6> <p>TIBC was not reported in this study.</p> </section> <section id="CD009532-sec-0081"> <h6 class="title">vi. Transferrin saturation</h6> <p>Transferrin saturation was not reported in this study.</p> </section> </section> <section id="CD009532-sec-0082"> <h5 class="title">(3) Health‐related quality of life and physical activity</h5> <p>No measures of health‐related quality of life or physical activity were used in this study. </p> </section> <section id="CD009532-sec-0083"> <h5 class="title">(4) Adverse effects</h5> <p>No serious adverse effects occurred during the trial. In donors who received oral iron supplementation, two cases of constipation and two cases of diarrhoea were reported. In addition, six donors who received oral iron supplementation reported gastric discomfort. A non‐severe headache in one donor was the only adverse event reported in the intravenous iron group. </p> <p>This study also compared the frequencies of restless leg syndrome, measured by the International Restless Legs Syndrome Study Group Severity Scale (IRLS) in each treatment group. A significant difference in IRLS score between treatment groups in favour of intravenous administration of iron was reported; however, no standard deviations were reported to enable an estimation of the effect size. </p> </section> <section id="CD009532-sec-0084"> <h5 class="title">(5) Compliance</h5> <p>Treatment compliance (defined as 100% of medication taken) between visit four and seven ranged from 88% to 91.7% for oral iron supplementation compared with 88% to 100% for iron administered intravenously. </p> </section> </section> <section id="CD009532-sec-0085"> <h4 class="title">C. Iron supplementation versus iron‐rich food supplements</h4> <p>No studies comparing iron supplementation versus iron‐rich food supplements were identified.</p> </section> <section id="CD009532-sec-0086"> <h4 class="title">D. Iron supplementation, dose A versus iron supplementation, dose B</h4> <p>Four studies compared different doses of iron supplementation (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>). Details of the doses and duration of treatment in individual studies are given in <a href="#CD009532-tbl-0002">Table 1</a>. </p> <section id="CD009532-sec-0087"> <h5 class="title">(1) Risk ratio of low Hb deferral (primary outcome)</h5> <p>Two studies reported low Hb deferral at donation although in the first of these, discrepancies in the paper prevented reliable extraction of the data (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>). In the second study, there was no evidence for a difference in the rate of low Hb deferral between treatment groups either at the first donation visit after commencement of iron supplementation (RR 0.66; 95% CI 0.11 to 3.92; 351 participants; P value = 0.65), after subsequent donation visits (RR 1.87; 95% CI 0.17 to 20.33; 236 participants; P value = 0.61) or over cumulative donation visits (RR 0.98; 95% CI 0.25 to 3.90; 742 participants; P value = 0.98) (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>) (<a href="./references#CD009532-fig-0014" title="">Analysis 3.1</a>). </p> </section> <section id="CD009532-sec-0088"> <h5 class="title">(2) Hb levels, MCV, other blood indices and iron stores</h5> <section id="CD009532-sec-0089"> <h6 class="title">i. Haemoglobin (Hb)</h6> <p>Hb levels before further donation were reported in one study (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>), in which there was no evidence for a difference in haemoglobin levels at follow‐up between treatment dosage groups (MD 5.00 g/L; 95% CI ‐0.47 to 10.47; 85 participants; P value = 0.07) (<a href="./references#CD009532-fig-0015" title="">Analysis 3.2</a>). One study reported Hb levels after subsequent donation(s) (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>); however, this study reported results graphically and data extraction could not be undertaken; no significant differences between groups were reported in this study. </p> </section> <section id="CD009532-sec-0090"> <h6 class="title">ii. Mean corpuscular volume (MCV)</h6> <p>No studies reported MCV as an outcome.</p> </section> <section id="CD009532-sec-0091"> <h6 class="title">iii. Serum ferritin</h6> <p>Two studies reported serum ferritin levels at follow‐up before further donation (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>). Meta‐analysis of these two studies showed no evidence for a difference in serum ferritin between dosage groups (MD 2.89 ng/mL; 95% CI ‐1.83 to 7.60; two studies; 356 participants; P value = 0.23). However, in one study which reported serum ferritin level after two (female) or three (male) subsequent donations, there was a significant difference in serum ferritin in favour of a higher dose (20 mg twice daily compared with 10 mg twice daily) of iron supplementation (MD 7.96 ng/mL; 95% CI 1.68 to 14.24; 206 participants; P value = 0.01) (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>) (<a href="./references#CD009532-fig-0016" title="">Analysis 3.3</a>). </p> </section> <section id="CD009532-sec-0092"> <h6 class="title">iv. Serum or plasma iron</h6> <p>One study reported serum iron levels after subsequent donations (<a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>). There was no evidence for a difference in serum iron levels between treatment groups in this study (MD 21.00 μg/dL; 95% CI ‐7.70 to 49.70; 17 participants; P value = 0.15) (<a href="./references#CD009532-fig-0017" title="">Analysis 3.4</a>). A further study reported results graphically and data extraction could not be undertaken; no significant differences between groups were reported (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>). </p> </section> <section id="CD009532-sec-0093"> <h6 class="title">v. Total iron binding capacity (TIBC)</h6> <p>Two studies reported TIBC after subsequent donations (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>), although in the first of these results were reported graphically and no data extraction could be undertaken; this study reported no significant differences between treatment groups. In the second study, there was no evidence for a difference in TIBC between treatment groups (MD ‐27.00 μg/dL; 95% CI ‐78.22 to 24.22; 17 participants; P value = 0.30) (<a href="./references#CD009532-fig-0018" title="">Analysis 3.5</a>). </p> </section> <section id="CD009532-sec-0094"> <h6 class="title">vi. Transferrin saturation (%)</h6> <p>Transferrin saturation before further donation was reported in one study (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>), in which there was no evidence for a difference in transferrin saturation (MD 5.10%; 95% CI ‐0.46 to 10.66; 85 participants; P value = 0.07) (<a href="./references#CD009532-fig-0019" title="">Analysis 3.6</a>). No studies reported transferrin saturation after subsequent donation(s). </p> </section> </section> <section id="CD009532-sec-0095"> <h5 class="title">(3) Health‐related quality of life and physical activity</h5> <p>Physical capacity using a bike test was reported in one study (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>); however, no standard deviations were provided and therefore a formal assessment of these results was not possible. No significant differences between treatment groups were reported. </p> </section> <section id="CD009532-sec-0096"> <h5 class="title">(4) Adverse effects</h5> <p>Adverse effects were reported descriptively in two studies (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>), in which no significant differences in the frequency of adverse effects between treatment groups were found. Specific adverse effects were not reported. </p> </section> <section id="CD009532-sec-0097"> <h5 class="title">(5) Compliance</h5> <p>Compliance was measured in all four studies although was not reported in one study (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>), and no study reported compliance separately per treatment group. Two studies reported compliance as no more than 10 tablets forgotten during the whole period (<a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>; <a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a>), which occurred in all and 75% of participants respectively. In the third study compliance, defined as the ingestion of at least 90% of prescribed capsules, was poor in one‐third of male and one‐quarter of female participants (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>). </p> </section> </section> <section id="CD009532-sec-0098"> <h4 class="title">E. Iron supplementation, treatment duration A versus iron supplementation, treatment duration B </h4> <p>One study compared different durations of iron supplementation between groups (3108 mg over 28 days versus 444 mg over four days) (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>). </p> <section id="CD009532-sec-0099"> <h5 class="title">(1) Risk ratio of low Hb deferral (primary outcome)</h5> <p>Low Hb deferral was not reported in this study.</p> </section> <section id="CD009532-sec-0100"> <h5 class="title">(2) Hb levels, MCV, other blood indices and iron stores</h5> <section id="CD009532-sec-0101"> <h6 class="title">i. Haemoglobin (Hb)</h6> <p>Post‐treatment Hb levels before further donation visits were reported in this study; there was no evidence of a difference in Hb levels between treatment arms (MD 1.00 g/L; 95% CI ‐0.93 to 2.93; 123 participants; P value = 0.31) (<a href="./references#CD009532-fig-0020" title="">Analysis 4.1</a>). </p> </section> <section id="CD009532-sec-0102"> <h6 class="title">ii. Mean corpuscular volume (MCV)</h6> <p>MCV was not reported in this study.</p> </section> <section id="CD009532-sec-0103"> <h6 class="title">iii. Serum ferritin</h6> <p>Serum ferritin was not reported in this study.</p> </section> <section id="CD009532-sec-0104"> <h6 class="title">iv. Serum or plasma iron</h6> <p>Significantly higher plasma iron levels before further donation visits were found in donors who received iron supplementation for the longer treatment duration of 28 days (MD 24.12 μg/dL; 95% CI 9.36 to 38.88; 123 participants; P value = 0.001) (<a href="./references#CD009532-fig-0021" title="">Analysis 4.2</a>). </p> </section> <section id="CD009532-sec-0105"> <h6 class="title">v. Total iron binding capacity (TIBC)</h6> <p>TIBC was not reported in this study.</p> </section> <section id="CD009532-sec-0106"> <h6 class="title">vi. Transferrin saturation (%)</h6> <p>Significantly higher transferrin saturation levels before further donation visits between treatment arms were found in donors who received a longer treatment duration of iron supplementation (MD 4.81%; 95% CI 1.93 to 7.69; 123 participants; P value = 0.001) (<a href="./references#CD009532-fig-0022" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD009532-sec-0107"> <h5 class="title">(3) Health‐related quality of life and physical activity</h5> <p>No measures of health‐related quality of life or physical activity were used in this study. </p> </section> <section id="CD009532-sec-0108"> <h5 class="title">(4) Adverse effects</h5> <p>Mainly minor side effects were reported in 19% to 29% of donors; this study did not provide results separately for each treatment group. </p> </section> <section id="CD009532-sec-0109"> <h5 class="title">(5) Compliance</h5> <p>This study reported treatment compliance only in participants who received treatment for the longer period of 28 days; in these participants, tablets were taken on between 87.7% and 93.4% of total treatment days. </p> </section> </section> <section id="CD009532-sec-0110"> <h4 class="title">F. Iron supplementation, preparation A versus iron supplementation, preparation B</h4> <p>Twelve studies compared different preparations of iron supplementation, which included a comparison of ferrous sulphate versus ferrous fumarate (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>), ferrous sulphate versus carbonyl iron (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), ferrous sulphate versus two or three different doses of ferric polymaltose (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>), ferrous sulphate versus ferric protein succinylate (<a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>), two different preparations of ferrous sulphate (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>), and two different preparations of ferrous fumarate: heme iron versus non‐heme iron (<a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>), or non‐heme iron versus a lower dose of non‐heme iron but supplemented with heme iron (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>). </p> <p>Three studies reported Hb levels and other blood indices graphically (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>). In the first study, we estimated data from the graphs as described in the <a href="#CD009532-sec-0022">Methods</a> section (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>). However, in two studies, graphs were of insufficient quality to allow reliable data extraction (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), and in one case (<a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a>), did not include standard deviations. </p> <section id="CD009532-sec-0111"> <h5 class="title">(1) Risk ratio of low Hb deferral (primary outcome)</h5> <p>One study comparing ferrous sulphate with ferric polymaltose reported low Hb deferral rates (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>); however these data could not be extracted due to data discrepancies in the study report. </p> <p>In the comparison of ferrous sulphate with ferrous fumarate, there was no evidence from one study of a difference in the rate of low Hb deferral after multiple donation visits (RR 0.51; 95% CI 0.05 to 5.60; 419 participants; P value = 0.58) (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>) (<a href="./references#CD009532-fig-0023" title="">Analysis 5.1</a>). </p> </section> <section id="CD009532-sec-0112"> <h5 class="title">(2) Hb levels, MCV, other blood indices and iron stores</h5> <section id="CD009532-sec-0113"> <h6 class="title">i. Haemoglobin (Hb)</h6> <p>Two studies comparing ferrous sulphate and ferrous fumarate reported Hb levels (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>); there was no evidence for a difference in Hb levels between iron preparations either before further donation (MD 2.00; 95% CI ‐2.85 to 6.85; one study; 61 participants; P value = 0.42) (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>), or after two subsequent donations (MD 1.00 g/L; 95% CI ‐0.79 to 2.79; one study; 346 participants; P value = 0.27) (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>) (<a href="./references#CD009532-fig-0024" title="">Analysis 5.2</a>). </p> <p>In the comparison of ferrous sulphate with carbonyl iron, three studies reported Hb levels before further donation (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), although in one study data were reported graphically and could not be extracted (<a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>). Combined evidence from two studies showed no evidence for a difference in Hb levels between treatment arms (MD 0.76 g/L; 95% CI ‐2.98 to 4.49; two studies; 79 participants; P value = 0.69) (<a href="./references#CD009532-fig-0028" title="">Analysis 6.1</a>). </p> <p>Similarly, there was no evidence for a difference in Hb levels before further donation from three trials (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>), which compared ferrous sulphate with ferric compounds as iron preparations (MD 2.36 g/L; 95% CI ‐0.63 to 5.34; three studies; 261 participants; P value = 0.12) (<a href="./references#CD009532-fig-0035" title="">Analysis 7.1</a>). </p> <p>In the comparison of two preparations of ferrous fumarate (20 mg compared with 16 mg plus 2 mg heme iron from porcine blood), there was no evidence for a difference in mean change from baseline Hb levels (MD ‐20.0 g/L; 95% CI ‐80.59 to 40.59; one study; 34 participants; P value = 0.52) (<a href="./references#CD009532-fig-0042" title="">Analysis 9.1</a>). In another study (<a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>), which compared two different preparations of iron fumarate, Hb levels were reported as median values and therefore no formal assessment of the effect size could be undertaken. </p> </section> <section id="CD009532-sec-0114"> <h6 class="title">ii. Mean corpuscular volume (MCV)</h6> <p>Three studies which compared ferrous sulphate with carbonyl iron reported MCV before further donation (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), although graphical data reporting in one study precluded data extraction (<a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>). Combined evidence from two studies showed no difference in MCV after treatment (MD 0.62 fL; 95% CI ‐ 1.49 to 2.74; two studies; 79 participants; P value = 0.56) (<a href="./references#CD009532-fig-0029" title="">Analysis 6.2</a>). </p> <p>There was also no difference in MCV before further donation in a study of ferrous sulphate compared with ferric protein succinylate (MD 1.00 fL; 95% CI ‐1.09 to 3.09; 40 participants; P value = 0.35) (<a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>) (<a href="./references#CD009532-fig-0036" title="">Analysis 7.2</a>). </p> </section> <section id="CD009532-sec-0115"> <h6 class="title">iii. Serum ferritin</h6> <p>Serum ferritin levels before further donation were reported in three studies (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), which compared ferrous sulphate with carbonyl iron, although data from two studies could not be extracted (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), and one study reported geometric mean values (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>). </p> <p>There was also no evidence for a difference in serum ferritin levels before further donation from three studies (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>), which compared ferrous sulphate with ferrous compounds (MD 8.07 ng/mL; 95% CI ‐1.50 to 17.63; three studies; 261 participants; P value = 0.10) (<a href="./references#CD009532-fig-0037" title="">Analysis 7.3</a>). </p> <p>In the comparison of two preparations of ferrous fumarate (with and without heme iron), there was no evidence for a difference in mean change from baseline serum ferritin levels (MD ‐4.00 ng/mL; 95% CI ‐12.44 to 4.44; one study; 34 participants; P value = 0.35) (<a href="./references#CD009532-fig-0043" title="">Analysis 9.2</a>). Another study which compared different preparations of iron fumarate reported serum ferritin as median levels and therefore no formal assessment of the effect size could be undertaken (<a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>). </p> </section> <section id="CD009532-sec-0116"> <h6 class="title">iv. Serum or plasma iron</h6> <p>In two studies which compared serum iron levels between ferrous sulphate and ferrous fumarate preparations, there was no evidence for a difference in serum iron levels between treatment arms either before further donation (MD 7.00 μg/dL; 95% CI ‐7.14 to 21.14; one study; 61 participants; P value = 0.33) (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>), or after subsequent donations (MD 0.00 μg/dL; 95% CI ‐7.06 to 7.06; one study; 346 participants; P value = 1.00) (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>) (<a href="./references#CD009532-fig-0025" title="">Analysis 5.3</a>). </p> <p>Combined evidence from two studies (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>), which compared ferrous sulphate and carbonyl iron, also showed no difference in serum iron levels before further donation (MD ‐1.76 μg/dL; 95% CI ‐26.49 to 22.97; two studies; 79 participants; P value = 0.89) (<a href="./references#CD009532-fig-0030" title="">Analysis 6.3</a>). In a third study, graphical data were of insufficient quality to allow extraction (<a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>). </p> <p>Similarly, there was no evidence for a difference in serum iron levels between ferrous sulphate and ferric compound iron preparations before further donations (<a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>; <a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a>) (MD 0.88; 95% CI ‐3.25 to 5.00; two studies; 131 participants; P value = 0.68) (<a href="./references#CD009532-fig-0038" title="">Analysis 7.4</a>). </p> </section> <section id="CD009532-sec-0117"> <h6 class="title">v. Total iron binding capacity (TIBC)</h6> <p>There was no evidence for a difference in TIBC either before further donation (MD 0.00 μg/dL; 95% CI ‐3.76 to 3.76; one study; 61 participants; P value = 1.00) (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>), or after subsequent donations (MD 5.59 μg/dL; 95% CI ‐2.65 to 13.83; one study; 346 participants; P value = 0.18) (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>) (<a href="./references#CD009532-fig-0026" title="">Analysis 5.4</a>), in studies which compared ferrous sulphate with ferrous fumarate. </p> <p>There was also no evidence from two studies of a difference in TIBC before further donation between ferrous sulphate and carbonyl iron (MD ‐9.75 μg/dL; 95% CI ‐52.65 to 33.16; two studies; 79 participants; P value = 0.66) (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>) (<a href="./references#CD009532-fig-0031" title="">Analysis 6.4</a>). </p> <p>In the comparison of two preparations of ferrous fumarate (with and without heme iron), there was no evidence for a difference in mean change from baseline TIBC levels (MD 0.60 μg/dL; 95% CI ‐2.77 to 3.97; one study; 34 participants; P value = 0.73) (<a href="./references#CD009532-fig-0044" title="">Analysis 9.3</a>). </p> </section> <section id="CD009532-sec-0118"> <h6 class="title">vi. Transferrin saturation</h6> <p>Three studies which compared ferrous sulphate with carbonyl iron reported transferrin saturation (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), although two of these reported data graphically and the quality of the graphs in the latter study precluded data extraction (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>). Meta‐analysis of two studies showed no evidence for a difference in transferrin saturation between treatment arms (MD 2.45%; 95% CI ‐3.37 to 8.26; two studies; 79 studies; P value = 0.41) (<a href="./references#CD009532-fig-0032" title="">Analysis 6.5</a>). </p> <p>However, combined evidence from two studies, which compared ferrous sulphate with ferric polymaltose, showed significantly higher levels of transferrin saturation before further donation in donors who received ferrous sulphate (MD 5.33%; 95% CI 1.61 to 9.05 to; two studies; 221 participants; P value = 0.005), demonstrating a beneficial effect of ferrous sulphate over ferric polymaltose (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>) (<a href="./references#CD009532-fig-0039" title="">Analysis 7.5</a>). </p> </section> </section> <section id="CD009532-sec-0119"> <h5 class="title">(3) Health‐related quality of life and physical activity</h5> <p>No measures of health‐related quality of life or physical activity were used in studies which compared different iron preparations. </p> </section> <section id="CD009532-sec-0120"> <h5 class="title">(4) Adverse effects</h5> <p>In the comparison of ferrous sulphate with ferrous fumarate, one study showed a significant increase in overall adverse effects associated with ferrous sulphate (RR 1.40; 95% CI 1.04 to 1.88; 131 participants; P value = 0.03) (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>) (<a href="./references#CD009532-fig-0027" title="">Analysis 5.5</a>). However, there were no significant differences observed in individual studies (<a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>; <a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>), or from meta‐analysis of the frequencies of specific adverse effects, which included constipation, diarrhoea, nausea/vomiting and abdominal pain and/or cramps. </p> <p>There was no evidence for a difference in the overall frequency of adverse effects between ferrous sulphate and carbonyl iron from a meta‐analysis of two studies (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>) (RR 0.89; 95% CI 0.75 to 1.06; two studies; 96 participants; P value = 0.18) (<a href="./references#CD009532-fig-0033" title="">Analysis 6.6</a>), or in the frequency of specific adverse effects which included constipation, diarrhoea, nausea/vomiting, abdominal pain and/or cramps, gastric/epigastric pain and headache. However, carbonyl iron was associated with an increased risk of taste disturbances compared with ferrous sulphate (RR 0.43; 95% CI 0.25 to 0.74; two studies; 96 participants; P value = 0.002) (<a href="./references#CD009532-fig-0033" title="">Analysis 6.6</a>). </p> <p>Adverse effects were not reported in any of the studies which compared ferrous sulphate with ferric compound iron preparations. </p> <p>In the comparison of heme iron with non‐heme iron, one study reported a higher frequency of cumulative adverse effects for non‐heme iron than heme iron (25% versus 14%) (<a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a>), although the absence of actual numbers of participants prevented a statistical evaluation of this difference. In this study, participants who received non‐heme iron also experienced a higher rate of gastric pain (19% versus 6%), obstipation (35% versus 14%) and diarrhoea (37% versus 26%). </p> <p>In one study, which compared Eryfer<sup>Ⓡ</sup> with an alternative ferrous sulphate preparation (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>), a lower frequency of cumulative adverse effects was observed in participants who received Eryfer<sup>Ⓡ</sup> than in those who received the alternative preparation in both the morning (11.2% versus 4.7%) and the evening (10.0% versus 2.9%), although actual numbers were not reported and therefore no formal statistical assessment of these differences could be undertaken. In this study, adverse effects were predominantly gastrointestinal complaints, which included loss of appetite, indigestion and diarrhoea. In a second study, which compared ferrous sulphate with an alternative sustained release iron preparation (<a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>), there were no significant differences in the frequency of cumulative adverse effects (RR 1.14; 95% CI 0.91 to 1.43; 781 participants; P value = 0.26) or specific adverse effects including constipation, diarrhoea, nausea/vomiting and epigastric pain (<a href="./references#CD009532-fig-0040" title="">Analysis 8.1</a>). </p> </section> <section id="CD009532-sec-0121"> <h5 class="title">(5) Compliance</h5> <p>In the comparison of ferrous sulphate with ferrous fumarate, there was no difference in the number of participants who were 100% compliant over the treatment period (77.5% versus 82.5% respectively) (<a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>). </p> <p>In a meta‐analysis of two studies comparing ferrous sulphate with carbonyl iron (<a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a>), there was no difference in compliance between treatment arms (RR 0.95; 95% CI 0.84 to 1.09; two studies; 95 participants; P value = 0.48) (<a href="./references#CD009532-fig-0034" title="">Analysis 6.7</a>). A third study reported full compliance in both treatment arms (<a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a>). </p> <p>Compliance was reported descriptively in two studies (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>), which compared ferrous sulphate with ferric compound iron preparations; the first of these reported only that some patients stopped treatment due to adverse effects (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>). In the second study, tolerance was reported to be "much better with the complex exceeding 80% but this was only 60% with the ferrous sulphate" (<a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a>). </p> <p>The number of study participants who discontinued treatment was similar for ferrous sulphate and an alternative sustained‐release iron preparation (85.1% versus 86.6% respectively) (<a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>). However, in the study of Eryfer<sup>Ⓡ</sup>, compared with an alternative ferrous sulphate preparation (<a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>), compliance was significantly higher in participants who received Eryfer<sup>Ⓡ</sup> than in those who received the alternative preparation (RR 1.80; 95% CI 1.24 to 2.61; one study; 89 participants; P value = 0.002) (<a href="./references#CD009532-fig-0041" title="">Analysis 8.2</a>). We did not carry out meta‐analysis due to the differences in alternative iron preparation between the two studies. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009532-sec-0122" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009532-sec-0122"></div> <p>Iron deficiency is a significant cause of deferral in people wishing to donate blood. Donation intervals are set to minimise iron deficiency in repeat blood donors and all donors are screened pre‐donation at each repeat visit for low haemoglobin levels. Deferral of donation for a period of six months through failure to pass the haemoglobin threshold is associated with failure of donors to return to give blood. Avoiding iron deficiency is therefore essential not only to minimise symptoms and morbidity in donors and hence increase retention of donors in the long term, but also to maintain the efficiency of a donor session, where deferral is costly and disruptive. Iron supplementation for blood donors has been considered and in some settings has been implemented for certain groups of 'at risk' donors. Rigorous evidence for the cost and benefits of iron supplementation is essential to guide policy. </p> <section id="CD009532-sec-0123"> <h3 class="title" id="CD009532-sec-0123">Summary of main results</h3> <p><b>The relative and absolute benefits of iron supplementation</b> </p> <p>Thirty randomised controlled trials (RCTs) met the eligibility criteria, including comparisons of iron supplementation with placebo, as well as different methods of administration, doses, duration and preparations of iron supplementation. Meta‐analysis of four studies showed a significantly reduced risk of deferral due to low haemoglobin in donors who received iron supplementation compared with donors who received no iron supplementation, both at the first donation visit (risk ratio (RR) 0.34; 95% confidence interval (CI) 0.21 to 0.55; four studies; 1194 participants; P value &lt; 0.0001) and at subsequent donations (RR 0.25; 95% CI 0.15 to 0.41; three studies; 793 participants; P value &lt; 0.00001). There is also a clear benefit of iron supplementation on markers of iron stores but the effect of iron on haemoglobin level, although significant, is low. Detailed comparison of the effect of iron supplementation on iron stores is hampered by different assay methods and lack of standardisation. </p> <p>Based on data from the four studies, the absolute risk of deferral due to low Hb at the first donation visit after receiving iron supplementation is 3.6% in iron‐supplemented donors compared with 10.5% in controls. The corresponding absolute risks of deferral after multiple donation visits are 5.0% and 19.9% respectively, based on data from three studies. </p> <p>Evidence from a single study of parenteral versus oral iron suggests that parenteral iron is significantly more effective than oral iron in increasing serum ferritin levels. There may also be fewer minor side effects in donors given parenteral compared with oral iron, but widespread use of parenteral iron would not be practical in this population. However, this review has identified four ongoing randomised trials and one study awaiting classification which include iron administered intravenously to blood donors. Nevertheless, it seems unlikely that parenteral iron would be accepted on a mass scale, particularly given recent evidence from a systematic review that use of parenteral iron is associated with an increased risk of infection (<a href="./references#CD009532-bbs2-0078" title="LittonE , XiaoJ , HoKM . Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta‐analysis of randomised clinical trials. BMJ2013;347:f4822. ">Litton 2013</a>). </p> <p><b>Side effects of iron supplementation</b> </p> <p>The benefits of iron supplementation with tablets are substantial but the rate of significant side effects is high, which is likely to limit acceptability and compliance. However, adverse effects were widespread and were more frequent in donors who received iron supplementation than in those who did not (RR 1.60; 95% CI 1.23 to 2.07; four studies; 1748 participants; P value = 0.0005), with a significantly increased risk of gastrointestinal upset and taste disturbances. </p> <p>Due to the adverse effects associated with iron supplementation, treatment compliance is an issue. The absolute risk of adverse effects is 29% in iron‐supplemented donors compared with an absolute risk of 17% in controls. The impact of these side effects on compliance is uncertain. Although seven studies identified reasons for non‐compliance or discontinuation of treatment associated with adverse effects (<a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>; <a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>; <a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a>; <a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a>; <a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a>; <a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a>), only two trials reported compliance rates separately for both treatment groups (<a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a>) and, taken together, showed no evidence for a difference in compliance rates between treatment groups (RR 0.76; 95% CI 0.51 to 1.15; two studies; 146 participants; P value = 0.19). Compliance (as measured by ingestion of over 90% of tablets) was poorly documented in many of the studies but variable when reported (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). There are unlikely to be significant cost issues associated with iron supplements but compliance may be a more important issue if iron supplementation is targeted at large numbers of donors in routine operational practice. </p> <p>The long‐term effects of iron supplementation without measurement of iron stores are unknown and in other contexts iron given indiscriminately has had deleterious consequences in some populations (<a href="./references#CD009532-bbs2-0082" title="OppenheimerSJ . Iron and its relation to immunity and infectious disease. Journal of Nutrition2001;131(2):616S‐35S. ">Oppenheimer 2001</a>; <a href="./references#CD009532-bbs2-0085" title="SazawalS , BlackRE , RamsanM , ChwayaHM , StoltzfusRJ , DuttaA , et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community‐based, randomised, placebo‐controlled trial. Lancet2006;367(9505):133‐4. ">Sazawal 2006</a>). These considerations are likely to preclude widespread use of iron supplementation by tablets. </p> </section> <section id="CD009532-sec-0124"> <h3 class="title" id="CD009532-sec-0124">Overall completeness and applicability of evidence</h3> <p>There are very few studies of the effects of iron supplementation on physical capacity and quality of life in blood donors. </p> <p>Differences between studies in terms of type of participants, the preparation, dose and duration of treatment and the time at which outcomes were measured, as well as inter‐donation interval, inevitably limited investigation of the effect of iron supplementation on physical capacity and quality of life. There is very limited evidence in non‐blood donors that iron supplementation of iron‐deficient non‐anaemic adults improves some aspects of cognitive function (<a href="./references#CD009532-bbs2-0071" title="FalkinghamM , AbdelhamidA , CurtisP , Fairweather‐TaitS , DyeL , HooperL . The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta‐analysis. Nutrition Journal2010;9:4. ">Falkingham 2010</a>). Further evidence of the effect of iron stores on cognitive function and physical activity or capacity in donors from adequately powered RCTs would be crucial to inform future policies. </p> <p>It is possible that effects of iron supplementation on physical function may take place quickly and be found in trials of short‐term iron supplementation. However, immediately after donation these effects are confounded by fluctuations in haemoglobin. Furthermore, a reduction in physical or mental function may only be seen in those who are iron deficient over a longer period of time. While power calculations are difficult without more preliminary data, studies may indeed need larger sample sizes and longer follow‐up periods to see the effects of iron supplementation on wider measures of physical and mental function. </p> <p>One potentially very important question for further study is whether low and/or intermittent iron supplementation may have a similar effect in reducing anaemia and low haemoglobin deferral to a higher dose or continuous iron supplementation, but with reduced side effects. Only one study directly addressed different durations of iron supplementation in donors and compared iron supplementation of 3108 mg over 28 days versus 444 mg over four days (<a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>). Unfortunately, deferral due to low haemoglobin was not reported and adverse events were not discussed by study group. Our review can therefore only search for differences in outcomes among different trials of iron supplementation where iron was given for different durations. </p> <p>The combined evidence from all four studies where deferral rates were reported showed a significantly reduced risk of deferral due to low Hb at the first donation visit after treatment in donors who received iron supplementation (RR 0.34; 95% CI 0.21 to 0.55; four studies; 1194 participants; P value &lt; 0.0001) and this low Hb deferral risk reduction was maintained after multiple and/or cumulative donation visits, with no evidence of heterogeneity between studies (I<sup>2</sup> = 0%; 95% CI 0% to 79.3%) (<a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a>; <a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>; <a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a>). Furthermore, there were no significant differences between male and female donors in low Hb deferral rates at first donation, after multiple donation visits or over cumulative donation visits (<a href="./references#CD009532-fig-0045" title="">Analysis 10.1</a>; <a href="./references#CD009532-fig-0046" title="">Analysis 10.2</a>; <a href="./references#CD009532-fig-0047" title="">Analysis 10.3</a>). Looking at the effect of different iron dosing schedules on iron stores, meta‐analysis of two studies which reported serum ferritin levels at follow‐up before further donation showed no evidence for a difference in serum ferritin between dosage groups (<a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a>; <a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a>). However, in one study which reported serum ferritin levels after two (female) or three (male) subsequent donations, there was a significant difference in serum ferritin in favour of a higher dose (20 mg twice daily compared with 10 mg twice daily) of iron supplementation (<a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a> (<a href="./references#CD009532-fig-0016" title="">Analysis 3.3</a>). These differences did not translate into a significant difference in deferral rates. </p> <p>The question of the effect of duration or intensity of iron supplementation and outcome has been addressed in RCTs of iron supplementation in pregnancy and a recent Cochrane review of intermittent versus daily iron supplementation concluded that there was a reduced incidence of mild to moderate anaemia in women taking daily compared to intermittent iron supplements, but no differences in the incidence of adverse outcomes of the pregnancy or in the neonate, as far as could be ascertained. Nevertheless, there was a significantly reduced incidence of side effects in those women receiving intermittent compared to daily iron supplementation (RR 0.57; 95% CI 0.34 to 0.87) (<a href="./references#CD009532-bbs2-0083" title="Peña‐RosasJP , De‐RegilLM , DowswellT , ViteriFE . Intermittent oral iron supplementation during pregnancy. Cochrane Database of Systematic Reviews2012, Issue 7. [DOI: 10.1002/14651858.CD009997] ">Peña‐Rosas 2012</a>). </p> <p>One physiological explanation for the broadly similar effects of lower versus higher doses of iron is that absorption of iron is greater when iron stores are low and the proportion of iron absorbed is reduced as iron stores rise, reducing the benefit and possibly increasing the side effects as the dose and duration of iron supplementation is increased. Examining the benefits and adverse events of lower versus higher‐dose regimes of iron supplementation would quite clearly be a priority for further work. </p> <p>No trials were reported from lower‐middle‐income or low‐income counties. In many parts of the world recruitment of donors and blood safety has been the main focus of concern and research, while low deferral rates in repeat donors have been less of a priority. Nevertheless, in many parts of the world iron deficiency is very common (<a href="./references#CD009532-bbs2-0077" title="LimSS , VosT , FlaxmanAD , DanaeiG , ShibuyaK , Adair‐RohaniH , et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2012;380(9859):2224‐60. ">Lim 2012</a>; <a href="./references#CD009532-bbs2-0079" title="MillerJL . Iron deficiency anemia: a common and curable disease. Cold Spring Harbour Perspectives in Medicine2013;3(7):a011866. [DOI: 10.1101/cshperspect.a011866] ">Miller 2013</a>), and high deferral rates in first‐time donors who fail to meet the haemoglobin threshold are certainly observed. Iron replacement in areas where malaria and other protozoa or community‐acquired bacterial infections are prevalent may predispose to infection (<a href="./references#CD009532-bbs2-0069" title="DrakesmithH , PrenticeAM . Hepcidin and the iron‐infection axis. Science2012;338(6108):768‐72. ">Drakesmith 2012</a>), and it is likely that the question of iron replacement in donors will become an important topic of research in middle‐income and low‐income countries as the donor base increases and a higher proportion of donors are repeat donors. The safety of iron supplementation with regard to infection will require careful scrutiny in well‐designed trials, although it may be more straightforward to predict the likelihood of deferral to stratify donation intervals to reduce deferral in groups of donors at greater risk of iron deficiency. </p> <p>This review highlights the limited amount of data available for iron supplementation in the context of blood donation. The number of studies is limited for each comparison and they usually involve a small number of participants. Small study effects (bias) should be considered when interpreting the results. The majority of the data are from studies comparing iron supplementation versus placebo, but even there numbers are small. For example, only a few events are recorded in each study when looking at the effect of iron supplementation on low Hb deferral. </p> </section> <section id="CD009532-sec-0125"> <h3 class="title" id="CD009532-sec-0125">Quality of the evidence</h3> <p>Thirty RCTs including a total of 4704 participants met the eligibility criteria, including 19 comparisons of iron supplementation and placebo or control; one comparison of oral and parenteral iron supplementation; four comparisons of different doses of iron supplementation; one comparison of different treatment durations of iron supplementation; and 12 comparisons of different iron supplementation preparations. However, the number of studies included in meta‐analyses was limited by differences in methods of outcome reporting, treatment duration and length of follow‐up between studies. The reduction in deferral due to low haemoglobin shows a large effect, but due to the risk of bias in the included studies we have downgraded the quality of the evidence to moderate (see 'Summary of findings' table). </p> <p>Heterogeneity confidence intervals for I<sup>2</sup> were generally wide due to the low number of studies included in each analysis. Visual inspection of forest plots revealed no obvious heterogeneity due to date of publication or study size. </p> </section> <section id="CD009532-sec-0126"> <h3 class="title" id="CD009532-sec-0126">Potential biases in the review process</h3> <p>The risk of bias was high or unclear in many studies, probably due to poor methods of reporting in studies published before 1990, including five that were published before 1980. Precise definition of the quality of studies is difficult as judgement is based on limited evidence, but there is no definitive evidence of substantial bias nor of systematic error through poor quality studies. </p> </section> <section id="CD009532-sec-0127"> <h3 class="title" id="CD009532-sec-0127">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, there are no other reviews in this area for comparison of our findings with other analyses. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009532-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram." data-id="CD009532-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD009532-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 1 Deferral due to low haemoglobin (primary outcome)." data-id="CD009532-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 1 Deferral due to low haemoglobin (primary outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 2 Haemoglobin (g/L)." data-id="CD009532-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 2 Haemoglobin (g/L).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 3 Mean cell volume (fL)." data-id="CD009532-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 3 Mean cell volume (fL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 4 Serum ferritin (ng/mL)." data-id="CD009532-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 4 Serum ferritin (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 5 Serum or plasma iron (μg/dL)." data-id="CD009532-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 5 Serum or plasma iron (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 6 Total iron blinding concentration (μg/dL)." data-id="CD009532-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 6 Total iron blinding concentration (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 7 Transferrin saturation (%)." data-id="CD009532-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 7 Transferrin saturation (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 8 Health‐related quality of life." data-id="CD009532-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 8 Health‐related quality of life. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 9 Adverse effects." data-id="CD009532-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 9 Adverse effects.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Iron supplementation versus placebo/control, Outcome 10 Compliance." data-id="CD009532-fig-0012" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Iron supplementation versus placebo/control, Outcome 10 Compliance.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Iron supplementation: oral versus parenteral, Outcome 1 Serum ferritin (ng/mL)." data-id="CD009532-fig-0013" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Iron supplementation: oral versus parenteral, Outcome 1 Serum ferritin (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron supplementation: high dose versus low dose, Outcome 1 Deferral due to low haemoglobin (primary outcome)." data-id="CD009532-fig-0014" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Iron supplementation: high dose versus low dose, Outcome 1 Deferral due to low haemoglobin (primary outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron supplementation: high dose versus low dose, Outcome 2 Haemoglobin (g/L)." data-id="CD009532-fig-0015" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Iron supplementation: high dose versus low dose, Outcome 2 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron supplementation: high dose versus low dose, Outcome 3 Serum ferritin (ng/mL)." data-id="CD009532-fig-0016" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Iron supplementation: high dose versus low dose, Outcome 3 Serum ferritin (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron supplementation: high dose versus low dose, Outcome 4 Serum or plasma iron (μg/dL)." data-id="CD009532-fig-0017" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Iron supplementation: high dose versus low dose, Outcome 4 Serum or plasma iron (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron supplementation: high dose versus low dose, Outcome 5 Total iron binding concentration (μg/dL)." data-id="CD009532-fig-0018" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Iron supplementation: high dose versus low dose, Outcome 5 Total iron binding concentration (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Iron supplementation: high dose versus low dose, Outcome 6 Transferrin saturation (%)." data-id="CD009532-fig-0019" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Iron supplementation: high dose versus low dose, Outcome 6 Transferrin saturation (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Iron supplementation: long versus short treatment duration, Outcome 1 Haemoglobin (g/L)." data-id="CD009532-fig-0020" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Iron supplementation: long versus short treatment duration, Outcome 1 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Iron supplementation: long versus short treatment duration, Outcome 2 Serum or plasma iron (μg/dL)." data-id="CD009532-fig-0021" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Iron supplementation: long versus short treatment duration, Outcome 2 Serum or plasma iron (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Iron supplementation: long versus short treatment duration, Outcome 3 Transferrin saturation (%)." data-id="CD009532-fig-0022" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Iron supplementation: long versus short treatment duration, Outcome 3 Transferrin saturation (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 1 Deferral due to low haemoglobin (primary outcome)." data-id="CD009532-fig-0023" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 1 Deferral due to low haemoglobin (primary outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 2 Haemoglobin (g/L)." data-id="CD009532-fig-0024" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 2 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 3 Serum or plasma iron (μg/dL)." data-id="CD009532-fig-0025" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 3 Serum or plasma iron (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 4 Total iron binding concentration (μg/dL)." data-id="CD009532-fig-0026" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 4 Total iron binding concentration (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 5 Adverse effects." data-id="CD009532-fig-0027" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Iron supplementation: ferrous sulphate versus ferrous fumarate, Outcome 5 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 1 Haemoglobin (g/L)." data-id="CD009532-fig-0028" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 1 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 2 Mean cell volume (fL)." data-id="CD009532-fig-0029" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 2 Mean cell volume (fL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 3 Serum or plasma iron (μg/dL)." data-id="CD009532-fig-0030" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 3 Serum or plasma iron (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 4 Total iron binding concentration (μg/dL)." data-id="CD009532-fig-0031" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 4 Total iron binding concentration (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 5 Transferrin saturation (%)." data-id="CD009532-fig-0032" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 5 Transferrin saturation (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 6 Adverse effects." data-id="CD009532-fig-0033" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.6</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 6 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-006-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-006-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 7 Compliance." data-id="CD009532-fig-0034" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.7</div> <div class="figure-caption"> <p>Comparison 6 Iron supplementation: ferrous sulphate versus carbonyl iron, Outcome 7 Compliance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-006-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 1 Haemoglobin (g/L)." data-id="CD009532-fig-0035" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 1 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 2 Mean cell volume (fL)." data-id="CD009532-fig-0036" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 2 Mean cell volume (fL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 3 Serum ferritin (ng/mL)." data-id="CD009532-fig-0037" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 3 Serum ferritin (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 4 Serum or plasma iron (μg/dL)." data-id="CD009532-fig-0038" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 4 Serum or plasma iron (μg/dL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 5 Transferrin saturation (%)." data-id="CD009532-fig-0039" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Iron supplementation: ferrous sulphate versus ferric compounds, Outcome 5 Transferrin saturation (%). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Iron supplementation: ferrous sulphate versus alternative preparation, Outcome 1 Adverse effects." data-id="CD009532-fig-0040" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Iron supplementation: ferrous sulphate versus alternative preparation, Outcome 1 Adverse effects. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Iron supplementation: ferrous sulphate versus alternative preparation, Outcome 2 Compliance." data-id="CD009532-fig-0041" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Iron supplementation: ferrous sulphate versus alternative preparation, Outcome 2 Compliance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme), Outcome 1 Haemoglobin (g/L) ‐ mean change from baseline." data-id="CD009532-fig-0042" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme), Outcome 1 Haemoglobin (g/L) ‐ mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme), Outcome 2 Serum ferritin (ng/mL) ‐ mean change from baseline." data-id="CD009532-fig-0043" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme), Outcome 2 Serum ferritin (ng/mL) ‐ mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme), Outcome 3 Total iron binding concentration (μg/dL) ‐ mean change from baseline." data-id="CD009532-fig-0044" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme), Outcome 3 Total iron binding concentration (μg/dL) ‐ mean change from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 1 Deferral due to low haemoglobin: at first donation visit after commencement of treatment." data-id="CD009532-fig-0045" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 1 Deferral due to low haemoglobin: at first donation visit after commencement of treatment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 2 Deferral due to low haemoglobin: after multiple donation visits." data-id="CD009532-fig-0046" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 2 Deferral due to low haemoglobin: after multiple donation visits. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 3 Deferral due to low haemoglobin: cumulative deferrals over all visits." data-id="CD009532-fig-0047" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 3 Deferral due to low haemoglobin: cumulative deferrals over all visits. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 4 Haemoglobin (g/L): before further donation." data-id="CD009532-fig-0048" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 4 Haemoglobin (g/L): before further donation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 5 Serum ferritin (ng/mL): before further donation." data-id="CD009532-fig-0049" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 5 Serum ferritin (ng/mL): before further donation. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 6 Serum ferritin (ng/mL): after subsequent donation(s)." data-id="CD009532-fig-0050" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Iron supplementation versus placebo/control: males versus females, Outcome 6 Serum ferritin (ng/mL): after subsequent donation(s). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Iron supplementation versus placebo/control: low risk of performance bias, Outcome 1 Deferral due to low haemoglobin (primary outcome)." data-id="CD009532-fig-0051" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Iron supplementation versus placebo/control: low risk of performance bias, Outcome 1 Deferral due to low haemoglobin (primary outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Iron supplementation versus placebo/control: low risk of performance bias, Outcome 2 Haemoglobin (g/L)." data-id="CD009532-fig-0052" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Iron supplementation versus placebo/control: low risk of performance bias, Outcome 2 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Iron supplementation versus placebo/control: low risk of performance bias, Outcome 3 Serum ferritin (ng/mL)." data-id="CD009532-fig-0053" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Iron supplementation versus placebo/control: low risk of performance bias, Outcome 3 Serum ferritin (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed, Outcome 1 Deferral due to low haemoglobin (primary outcome)." data-id="CD009532-fig-0054" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed, Outcome 1 Deferral due to low haemoglobin (primary outcome). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed, Outcome 2 Haemoglobin (g/L)." data-id="CD009532-fig-0055" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed, Outcome 2 Haemoglobin (g/L). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009532-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/urn:x-wiley:14651858:media:CD009532:CD009532-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_t/tCD009532-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed, Outcome 3 Serum ferritin (ng/mL)." data-id="CD009532-fig-0056" src="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed, Outcome 3 Serum ferritin (ng/mL). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/media/CDSR/CD009532/image_n/nCD009532-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009532-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Iron supplementation for iron deficiency and/or anaemia in blood donors</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Iron supplementation for iron deficiency and/or anaemia in blood donors</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients with iron deficiency and/or anaemia in blood donors<br/> <b>Settings:</b> national blood services<br/> <b>Intervention:</b> iron supplementation </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Iron supplementation</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Low Hb deferral ‐ at first donation visit after commencement of treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.34</b> <br/> (0.21 to 0.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>1194<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>36 per 1000</b> <br/> (22 to 58) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>10 per 1000</b> <br/> (6 to 15) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>237 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>81 per 1000</b> <br/> (50 to 130) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>Low Hb deferral ‐ after multiple donation visits</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p><b>RR 0.25</b> <br/> (0.15 to 0.41) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>793<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"></td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>199 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> <br/> (30 to 81) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Low<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>12 per 1000</b> <br/> (8 to 20) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>High<sup>1</sup> </b> </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>456 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>114 per 1000</b> <br/> (68 to 187) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hb (g/L) ‐ before further donation</b> <br/> Scale from: 123 to 152 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ before further donation in the control groups was<br/> <b>135.2 g/L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ before further donation in the intervention groups was<br/> <b>2.36 higher</b> <br/> (0.06 to 4.66 higher)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>847<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Hb (g/L) ‐ after subsequent donation(s)</b> <br/> Scale from: 127.3 to 129 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ after subsequent donation(s) in the control groups was<br/> <b>127.8 g/L</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Hb (g/L) ‐ after subsequent donation(s) in the intervention groups was<br/> <b>6.37 higher</b> <br/> (2.36 to 10.39 higher)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>406<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin (ng/mL) ‐ before further donation</b> <br/> Scale from: 12.9 to 57.8 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ before further donation in the control groups was<br/> <b>21.1 ng/mL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ before further donation in the intervention groups was<br/> <b>13.98 higher</b> <br/> (8.92 to 19.03 higher)<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>640<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serum ferritin (ng/mL) ‐ after subsequent donation(s)</b> <br/> Scale from: 18 to 19 </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ after subsequent donation(s) in the control groups was<br/> <b>18.6 ng/mL</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean serum ferritin (ng/mL) ‐ after subsequent donation(s) in the intervention groups was<br/> <b>9.01 higher</b> <br/> (5.76 to 12.25 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>619<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects (any)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>171 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> <br/> (210 to 354) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.6</b> <br/> (1.23 to 2.07) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1748<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>Hb:</b> haemoglobin; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Control risks will depend on study‐specific low haemoglobin deferral thresholds. Low and high control risks correspond to the minimum and maximum control risks in the included studies.<br/> <sup>2</sup>Most of the information is from studies with an unclear risk of bias. All but one study had a high risk of attrition bias and two studies were partially commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>3</sup>The range of scores is based on the lowest and highest estimate of the scores in the control groups in individual trials.<br/> <sup>4</sup>Most of the information is from studies with an unclear risk of bias. Four studies had a high risk of attrition bias, one study received assistance with data analysis from suppliers of the iron supplementation and one study did not blind participants. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>5</sup>Most of the information is from studies with an unclear risk of bias. All studies had a high risk of attrition bias. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>6</sup>Most of the information is from studies with an unclear risk of bias. Two studies had a high risk of attrition bias and one study was partially commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>7</sup>Most of the information is from studies with an unclear risk of bias. All studies had a high risk of attrition bias and one study was partially commercially funded. Potential limitations are likely to lower confidence in the estimate of the effect.<br/> <sup>8</sup>Most of the information is from studies with an unclear risk of bias. Two studies had a high risk of attrition bias. Potential limitations are likely to lower confidence in the estimate of the effect. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Iron supplementation for iron deficiency and/or anaemia in blood donors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009532-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study<sup>a</sup> </b> </p> <p><b> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention<sup>b</sup> (elemental iron dose)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Reported outcomes<sup>c</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow‐up time points<sup>d</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Description of study participants</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Duraferon) (100 mg daily for 20 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, RLS, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Week 4 and week 8 (non‐donation); donation 2 to 4 (♀) or  2 to 5 (♂); last donation is ≥ 1 year post‐1<sup>st</sup> donation </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Experienced donors having given at least 5 donations in last 1 to 2 years</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup>sucrose (Venofer) (1 x 200 mg given intravenously) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0002" title="BlotI , ChenayerM , DiakhateL , LelucR , GrossE , TcherniaG . Iron reserves in blood donors. Should we prescribe systematic iron supplementation? [Etude des reserves en fer chez les donneurs de sang. Faut‐il prescrire une supplementation martiale systematique?]. Revue Francaise de Transfusion et Immuno‐Hematologie1980;23(2):119‐29. [PUBMED: 7455480] ">Blot 1980</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> + Vit C (Ferro‐Grad Abbott) (105 mg (+ 500 mg Vit C) daily for "following months") </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, MCV, SeFe, TIBC, AE, SI, Sat</p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>At second donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0003" title="Borch‐IohnsenB , HalvorsenR , StenbergV , FleslandO , MowinckelP . The effect of daily low‐dose iron supplements in female blood donors with depleted iron stores: comparison with female non‐donors. Scandinavian Journal of Clinical and Laboratory Investigation1993;53(8):789‐91. ">Borch‐Iohnsen 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate + Vit C (Collett Iron) (20 mg (+ 120 mg Vit C) daily, treatment duration unclear) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, transferrin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 months after baseline measures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female blood donors with depleted iron stores (serum ferritin &lt; 20 μg/L and haemoglobin &gt; 120 g/L) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Vitalia Hemojern) (16 mg (+ 2 mg heme iron from porcine blood) daily, treatment duration unclear) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0004" title="BrittenhamGM , GordeukVR , BravoJR , HirschlerNV , PiliavinJA , GoormasticM , et al. Carbonyl iron supplementation for female blood donors. Blood. 1996; Vol. 88; 10 Suppl Pt 2:89b; Abstract 3085. ">Brittenham 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (100 mg daily for 56 days) with scheduled visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Mean no. donations per year</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 30 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Females pledged to donate four times each year.</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (scheduled visits only)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009532-bbs2-0005" title="BucherU , BaumannE , KellerT . Iron substitution in blood donors. II. Practical experience with iron substitution [Eisensubstitution bei Blutspendern. II. Praktische Erfahrungen mit der Eisensubstitution]. Schweizerische Medizinische Wochenschrift1973;103(46):1634‐40. [PUBMED: 4751063] ">Bucher 1973</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Resoferon) (37 mg 3 times daily for 28 days (one vial)) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Low Hb deferral, Hb, Hct, MCHC, transferrin, AE, PI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Day 14 and day 28 post‐donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Healthy blood donors blood group B; haemoglobin 125 to 135 g/L</p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Resoferon) (37 mg 3 times daily for 28 days (28 sachets)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Resoferon) (37 mg 3 times daily for 4 days (4 sachets) followed by placebo for 24 days (24 sachets)) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (3 times daily for 28 days (1 vial))</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0006" title="BuschH , GohrbandtG . Prevention of iron deficiency conditions in blood donors. Tolerance studies using the new iron preparation Eryfer [Zur Propylaxe von eisenmangelzustanden bei Blutspendern. Vertraglichkeitsstudie mit dem neuen eisenpraparat Eryfer]. Munchener Medizinische Wochenschrift (1950)1972;114(36):1543‐6. [PUBMED: 4561493] ">Busch 1972</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Eryfer) (50 mg (+ 222 mg Vit C + 84 mg NaHCO<sub>3</sub>) twice daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>After 30 days of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Blood donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (alternative) (50 mg (+ 222 mg Vit C) twice daily for 30 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (273.8 mg maize starch + 1.2 mg Aerosil twice daily for 30 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0007" title="BuziE , SiegenthalerP . Iron substitution in blood donors. Two different iron preparations from the galenic viewpoint [Substitution de fer chez les donneurs de sang. Etudes portant sur deux preparations de fer differentes au point de vue galenique]. Schweizerische Rundschau fur Medizin Praxis = Revue Suisse de Medecine Praxis1980;69(47):1744‐7. [PUBMED: 7255330] ">Buzi 1980</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Tardyferon) (80 mg (+ 80 mg muco‐protein) daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, Hct, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 2 after end of treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Deferred donors with Hb &lt; 130 g/L  (Hct &lt; 37%) and no history of medical pathology for anaemia </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (66 mg twice daily for 18 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0008" title="CableRG , MorseEE , KeltonicJ , KakaiyaR , KiralyT . Iron supplementation in female blood donors deferred by copper sulfate screening. Transfusion1988;28(5):422‐6. [PUBMED: 3047920] ">Cable 1988</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> gluconate (Fergon) (37.5 mg twice daily for trial duration) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, SeFe, transferrin, ZP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ 8 weeks since previous donation or 4 weeks since deferral, for 5 visits including initial visit </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female donors failing previous Hb screen (some were eligible to donate at start of study) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (calcium phosphate twice daily) for trial duration</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0009" title="DevasthaliSD , GordeukVR , BrittenhamGM , BravoJR , HughesMA , KeatingLJ . Bioavailability of carbonyl iron: a randomized, double‐blind study. European Journal of Haematology1991;46(5):272‐8. [PUBMED: 2044721] ">Devasthali 1991</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (100 mg daily for 84 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, MCV, SeFe, transferrin, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weeks 0, 1, 3, 6, 12, 16 (none were donation visits)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Menstruating, non‐pregnant women 18 to 40 years old recently deferred from donation (Hct &lt; 35%) with an absence of known medical disorders and no iron supplementation since deferral from blood donation and a MCV &lt; 85 fL and ferritin &lt; 12 μg/L </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (100 mg daily for 84 days) </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0010" title="AdolfssonL , EhnL , LiedenG , OldfeltCO . Blood donors' needs of iron (II) [Jarnbehov hos blodgivare (II)]. Lakartidningen1968;65(51):5109‐14. EhnL , LiedenG , OldfeltCO . Need of iron in blood donors [Jarnbehov hos blodgivare]. Lakartidningen1968;65(7):687‐97. [PUBMED: 5723566] LiedenG . Iron supplement to blood donors. I. Trials with intermittent iron supply. Acta Medica Scandinavica1975;197(1‐2):31‐6. [PUBMED: 1092131] ">Ehn 1968</a>* (Adolfsson 1968*; </p> <p>Lieden</p> <p>1975)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> succinate (Ferromyn S) (74 mg (+220 mg succinic acid) twice daily for 2 weeks) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hb, Hct, TIBC, PA, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>2 months after 6 subsequent donations (inter‐donation interval 2 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Young, healthy, male conscripts with no past history of haematological, gastrointestinal or renal disorder. None had previous haemorrhage or had served as blood donors </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> succinate (Ferromyn S) (34 mg (+110 mg succinic acid) twice daily for 2 weeks) </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 2 weeks)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0011" title="FrykmanE , BystromM , JanssonU , EdbergA , HansenT . Side effects of iron supplements in blood donors: superior tolerance of heme iron. Journal of Laboratory and Clinical Medicine1994;123(4):561‐4. [PUBMED: 8145004] ">Frykman 1994</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Hemofer) (8 mg (+1.2 mg heme iron from porcine blood) twice daily for first month then second or third month) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 3 months</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular blood donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Erco‐Fer) (60 mg daily for first month then second or third month) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0012" title="GordeukVR , BrittenhamGM , HughesMA , KeatingLJ . Carbonyl iron for short‐term supplementation in female blood donors. Transfusion1987;27(1):80‐5. [PUBMED: 3810831] ">Gordeuk 1987a</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (600 mg 3 times daily for 7 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hb, MCV, SeFe, TIBC, AE, SI, Sat,  FEP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Day 56 after successful donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Previous (at least once) female donors  of child‐bearing age who were not pregnant and came to donate blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (60 mg 3 times daily for 7 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (3 times daily for 7 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0013" title="GordeukVR , BrittenhamGM , HughesM , KeatingLJ , OppltJJ . High‐dose carbonyl iron for iron deficiency anemia: a randomized double‐blind trial. American Journal of Clinical Nutrition1987;46(6):1029‐34. [PUBMED: 3318377] ">Gordeuk 1987b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (600 mg 3 times daily for 21 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, MCV, SeFe, TIBC, AE, SI, Sat,  FEP</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Weeks 1, 3, 6, 12, 16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female blood donors of child‐bearing age who were not pregnant recently deferred from repeat donation due to low Hct </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (60 mg 3 times daily for 21 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0014" title="GordeukVR , BrittenhamGM , BravoJ , HughesMA , KeatingLJ . Prevention of iron deficiency with carbonyl iron in female blood donors. Transfusion1990;30(3):239‐45. [PUBMED: 2180144] GordeukVR , BrittenhamGM , BravoJA , HughesMA , KeatingLJ . Prevention of iron deficiency in female blood donors with short term carbonyl iron therapy. Blood. 29th Annual Meeting of the American Society of Hematology; 1987 Dec 4‐8; Washington (DC). 1987; Vol. 5 Suppl 1:329a; Abstract 1172. ">Gordeuk 1990</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbonyl iron (100 mg daily for 56 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, MCV, SeFe, transferrin, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 56 after successful donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Repeat female donors  of child‐bearing age who were not pregnant and came to donate blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0015" title="JacobsP , FransmanD , CoghlanP . Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron‐deficient blood donors. Journal of Clinical Apheresis1993;8(2):89‐95. [PUBMED: 8226711] ">Jacobs 1993</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (60 mg twice daily for 84 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Low Hb deferral, Hb, SeFe, NIA, AE, SI, Sat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Weeks 1, 2, 4, 8, 12. Not donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Donors failing CuSO4 Hb screening test, i.e. deferred donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><a href="./references#CD009532-bbs2-0016" title="JacobsP , WoodL , BirdAR . Erythrocytes: better tolerance of iron polymaltose complex compared with ferrous sulphate in the treatment of anaemia. Hematology (Amsterdam, Netherlands)2000;5(1):77‐83. [PUBMED: 11399604] ">Jacobs 2000</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg (+3.6 mMol/L GlyP) twice daily for 84 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Hb, SeFe, transferrin, AE, SI, RCF</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Weeks 4, 8 and 12. Not donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Regular donors failing CuSO4 Hb screening test</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg (+1.9 mMol/L GlyP) twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (100 mg twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> ("equivalent dose" twice daily for 84 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0017" title="LanducciG , FrontespeziS . Treatment of iron deficiency conditions in blood donors: controlled study of iron sulphate versus iron protein succinylate. Journal of International Medical Research1987;15(6):379‐82. [PUBMED: 3325320] ">Landucci 1987</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> protein succinylate (Legofer) (80 mg daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, Hct, MCV, MCH, MCHC, SeFe, transferrin, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>End of trial: mean 30 +/‐ 2.2 days (range 23 to 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Blood donors aged 18 to 56 with low levels of stored iron (serum ferritin &lt; 30 ng/100 mL) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (105 mg daily for 30 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0018" title="LiedenG , EhnL , HöglundS , ReizensteinP . Difficulties in preventing iron deficiency in blood donors. European Journal of Clinical Investigation1973;3:250. LiedenG , HöglundS , EhnL . Iron supplement to blood donors. II. Effect of continuous iron supply. Acta Medica Scandinavica1975;197(1‐2):37‐41. [PUBMED: 1124659] ">Lieden 1975</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> carbonate (100 mg daily for 1 year) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, TIBC, NIA, AE, SI, PCV</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 4th and 6th donations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Young, male, first‐time donor conscripts with no history of bleeding</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup>carbonate (20 mg daily for 1 year) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0019" title="LindholmA , CreutzerB , SkinhojA . Iron supplement to blood donors: a comparative study of two iron preparations. Opuscula Medica1981;26(4):134‐7. ">Lindholm 1981</a>* </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (ACO) (100 mg daily for 30 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, TIBC, AE, SI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 1st, 2nd and 3rd  donations</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Previous donors (all except 14/500) without iron deficiency anaemia during the most recent years, could tolerate different iron preparations and intended to continue to give blood </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> fumarate (Erco‐Fer) (60 mg daily for 30 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0020" title="LinpisarnS , KunachiwaW , LaokuldilokT , LaokuldilokJ , KeawvichitR , KulapongsP . Iron status and the effect of iron supplementation in Thai male blood donors in northern Thailand. Southeast Asian Journal of Tropical Medicine and Public Health1986;17(2):177‐83. [PUBMED: 3787305] ">Linpisarn 1986</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Elemental"” iron (56 mg daily for 90 days)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, Hct, SeFe, transferrin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After ˜3 months (assumed no donations)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Male volunteer and paid blood donors who had previously donated</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 90 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0022" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_LSF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (Ferrimed DS) (100 mg twice daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 56 days of treatment (not donation visit)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular donors (at least 4 donations in previous year) passing the Hb test and with low serum ferritin (less than 20 μg/L) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0021" title="MackintoshW , JacobsP . Response in serum ferritin and haemoglobin to iron therapy in blood donors. American Journal of Hematology1988;27:17‐9. ">Mackintosh 1988_HSF</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>3+</sup> polymaltose (Ferrimed DS) (100 mg twice daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>After 56 days of treatment (not donation visit)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular donors (at least 4 donations in previous year) passing the Hb test and with high serum ferritin (between 50 and 150 μg/L) </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0023" title="MaghsudluM , NasizadehS , ToogehGR , ZandiehT , ParandoushS , RezayaniM . Short‐term ferrous sulfate supplementation in female blood donors. Transfusion2008;48(6):1192‐7. [PUBMED: 18363581] MaghsudluM , ZandiehT , TogehGH , ParandushS , RezaianiM . Effect of short‐term ferrous sulfate on iron stores in female blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion (ISBT); 2006 Sept; Madrid. 2007; Vol. 93 Suppl 1:69‐70; Abstract P‐044. ">Maghsudlu 2008</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (150 mg 3 times daily for 7 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral, Hb, Hct, SeFe, TIBC, AE, SI, Sat</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Visits 1 (4 months), 2 (8 months) and 3 (12 months)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Female, successful blood donors &lt; 45 years who were not pregnant</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (3 times daily for 7 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0024" title="MirrezaieSM , ParsiR , TorabgahromiSA , AskarianM . Low dose, short‐term iron supplementation in female blood donors of childbearing age: a randomized, double‐masked, placebo‐controlled study. Iranian Journal of Medical Sciences2008;33(3):138‐43. ">Mirrezaie 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (50 mg daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>SeFe, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 7, 28 and 56. Not donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular (at least 2 donations in past year) healthy female donors of childbearing age. 72% had previously been taking iron supplements </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0025" title="KiesewetterH , TegtmeierJ , SalamaA , RadtkeH . Comparison of iron loss in whole blood donors. Vox Sanguinis. XVth Regional Congress of the International Society of Blood Transfusion; 2005 July 2; Athens. 2005; Vol. 89 Suppl 1:38. RadtkeH , MayerB , RockerL , SalamaA , KiesewetterH . Iron supplementation and 2‐unit red blood cell apheresis: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1463‐7. [PUBMED: 15383019] ">Radtke 2004a</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> gluconate (20 mg (+ 400 mg Vit C) twice daily for 6 months) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Low Hb deferral, SeFe, transferrin, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>♂ = 2/4/6 months; ♀ = 3/6 months. All were donation visits</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Regular, healthy donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> gluconate (+ 400 mg Vit C) (10 mg twice daily for 6 months) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (+400 mg Vit C) (twice daily for 6 months)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0026" title="RadtkeH , TegtmeierJ , RockerL , SalamaA , KiesewetterH . Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double‐blind, placebo‐controlled study. Transfusion2004;44(10):1427‐32. [PUBMED: 15383014] ">Radtke 2004b</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> Glycine SO<sub>4</sub> (ferro sanol duodenal) (100 mg daily for 8 to 10 weeks) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Low Hb deferral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Before donation visits 1, 2, 3 Inter‐donation interval 8 to 10 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Regular, healthy donors with a minimum body weight of 68 kg and Hb of 145 g/L giving 2‐unit RBC by apheresis </p> <p> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 8 to 10 weeks)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0027" title="RosvikAS , HervigT , Wentzel‐LarsenT , UlvikRJ . Effect of iron supplementation on iron status during the first week after blood donation. Vox Sanguinis2010;98(3 Pt 1):e249‐56. [PUBMED: 19874572] ">Rosvik 2010</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup> Glycine SO<sub>4</sub> (Niferex©) (100 mg daily for 8 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, transferrin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Day 8 (+/‐ 2) after initial donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Donors with at least 1 prior donation</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Control (no placebo)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0028" title="RyboG , SolvellL . Side‐effect studies on a new sustained release iron preparation. Scandinavian Journal of Haematology1971;8(4):257‐64. [PUBMED: 5134472] ">Rybo 1971</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (100 mg twice daily for 14 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Day 14 post‐donation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Regular blood donors</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> heptahydrate (100 mg twice daily for 14 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (twice daily for 14 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD009532-bbs2-0029" title="SimonTL , GarryPJ . Iron supplementation of menstruating female blood donors. Transfusion1981;21(5):634. SimonTL , HuntWC , GarryPJ . Iron supplementation for menstruating female blood donors. Transfusion1984;24(6):469‐72. [PUBMED: 6506175] ">Simon 1984</a> </p> <p> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub>  (37 mg daily for 56 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Hb, SeFe, TIBC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Donation visits 2, 3, 4, 5 etc. (inter‐donation interval 8 to 12 weeks, mean 9.5 weeks) with at least 4 donation visits </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Regular, female blood donors committing to donate blood every 8 weeks for 1 year</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub>  (37 mg (+75 mg Vit C) daily for 56 days) </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(100 mg Vit C daily for 56 days)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD009532-bbs2-0030" title="PedrazziniB , WaldvogelS , CornuzJ , VaucherP , BizeR , TissotJD , et al. The impact of iron supplementation efficiency in female blood donors with a decreased ferritin level and no anaemia. Rationale and design of a randomised controlled trial: a study protocol. Trials2009;10:4. WaldvogelS , PedrazziniB , VaucherP , BizeR , CornuzJ , TissotJD , et al. Clinical evaluation of iron treatment efficiency among non‐anemic but iron‐deficient female blood donors: a randomized controlled trial. BMC Medicine2012;10:8. [PUBMED: 22272750] ">Waldvogel 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fe<sup>2+</sup>SO<sub>4</sub> (Tardyferon) (80 mg daily for 28 days) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Hb, SeFe, Cog, PA, AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1 week after donation (randomisation) and 4 weeks post‐randomisation</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Successful female blood donors (non‐anaemic but iron‐deficient after donation)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo (daily for 28 days)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup>* = translated. </p> <p><sup>b</sup>Fe<sup>2+</sup> SO<sub>4</sub> = iron (II) sulphate; Fe<sup>3+</sup>sucrose = iron (III) sucrose; Fe<sup>2+</sup> = ferrous (II) salt; Fe<sup>3+</sup> = ferric (III) salt; NaHCO<sub>3</sub> = sodium bicarbonate; Vit C = vitamin C; GlyP = glycerophosphate. All treatments were administered orally with the exception of ferric sucrose, given intravenously in <a href="./references#CD009532-bbs2-0001" title="BirgegardG , SchneiderK , UlfbergJ . High incidence of iron depletion and restless leg syndrome (RLS) in regular blood donors: intravenous iron sucrose substitution more effective than oral iron. Vox Sanguinis2010;99(4):354‐61. [PUBMED: 20598107] SchneiderK , BirgegardG , UlfbergJ . Healthy blood donors are iron deficient!. Transfusion. 59th Annual Meeting of the American Association of Blood Banks; 2006 Oct. 2006; Vol. 49 Suppl 9:83A; Abstract SP144. ">Birgegard 2010</a>.  </p> <p><sup>c</sup>AE = adverse effects; Cog = cognitive function; FEP = free erythrocyte protoporphyrin; Hb = haemoglobin; Hct = haematocrit; MCH = mean cell Hb; MCHC = MCH concentration; MCV = mean cell volume; NIA = net iron absorption; PA = physical activity; PI = plasma iron; RLS = restless legs syndrome; Sat = percentage saturation; SeFe =serum ferritin; SI = serum iron; TIBC = total iron binding concentration; ZP = zinc protoporphyrin </p> <p><sup>d</sup>♂ = males, ♀ = females. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/full#CD009532-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Iron supplementation versus placebo/control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deferral due to low haemoglobin (primary outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Deferral at first donation visit after commencement of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1194</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.21, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Deferral after multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.15, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cumulative deferrals over multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2740</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.18, 0.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>847</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [0.06, 4.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.37 [2.36, 10.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Mean cell volume (fL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.37 [‐0.17, 2.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>640</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.98 [8.92, 19.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>9.01 [5.76, 12.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum or plasma iron (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.76 [‐1.67, 25.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.89 [1.12, 14.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Total iron blinding concentration (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐32.05 [‐61.45, ‐2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 After subsequent donations</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>315</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐42.64 [‐56.99, ‐28.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Transferrin saturation (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.91 [2.02, 5.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>343</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.84 [2.78, 6.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Health‐related quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Visual analogue scale fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Fatigue severity scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Vitality (SF‐12V2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.4 Chester step test (mL O2/kg/min)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.5 QoL (SF12NL: physical condition)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.6 QoL (SF12NL: mental condition)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Cumulative adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1748</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.23, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1849</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.16, 2.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1555</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.17 [1.38, 3.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.4 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.75 [1.20, 2.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.5 Abdominal pain and/or cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>683</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.21 [0.95, 5.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.6 Gastric or epigastric pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1242</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [0.73, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.7 Taste disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.78 [2.10, 15.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.8 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.53, 1.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Compliance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Non‐discontinuation of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1336</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.68, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 High compliance (&gt; 90%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.51, 1.15]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Iron supplementation versus placebo/control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Iron supplementation: oral versus parenteral</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Iron supplementation: oral versus parenteral</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Iron supplementation: high dose versus low dose</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deferral due to low haemoglobin (primary outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Deferral at first donation visit after commencement of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Deferral after multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cumulative deferrals over multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>356</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.89 [‐1.83, 7.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>206</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.96 [1.68, 14.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum or plasma iron (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Total iron binding concentration (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Transferrin saturation (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Iron supplementation: high dose versus low dose</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Iron supplementation: long versus short treatment duration</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum or plasma iron (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Transferrin saturation (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Iron supplementation: long versus short treatment duration</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus ferrous fumarate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deferral due to low haemoglobin (primary outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Deferral after multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum or plasma iron (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total iron binding concentration (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 After subsequent donation(s)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Cumulative adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.40 [1.04, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>433</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [0.78, 2.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.36, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.04, 3.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.5 Abdominal pain and/or cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.05, 6.53]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus ferrous fumarate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus carbonyl iron</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [‐2.98, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean cell volume (fL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [‐1.49, 2.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum or plasma iron (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.76 [‐26.49, 22.97]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Total iron binding concentration (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.75 [‐52.65, 33.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Transferrin saturation (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [‐3.37, 8.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Cumulative adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.75, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.40, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.05, 6.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.4 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.68, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.5 Abdominal pain and/or cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.10, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.6 Gastric or epigastric pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.25, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.7 Taste disturbances</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.25, 0.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.8 Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>143</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.46, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Compliance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.84, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus carbonyl iron</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus ferric compounds</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [‐0.63, 5.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Mean cell volume (fL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.07 [‐1.50, 17.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Serum or plasma iron (μg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [‐3.25, 5.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Transferrin saturation (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>221</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.33 [1.61, 9.05]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus ferric compounds</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus alternative preparation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Adverse effects <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Cumulative adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Gastric or epigastric pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Compliance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Non‐discontinuation of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Iron supplementation: ferrous sulphate versus alternative preparation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Haemoglobin (g/L) ‐ mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Serum ferritin (ng/mL) ‐ mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Total iron binding concentration (μg/dL) ‐ mean change from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Iron supplementation: ferrous fumarate (20 mg non‐heme versus 16 mg non‐heme with 2 mg heme)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Iron supplementation versus placebo/control: males versus females</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deferral due to low haemoglobin: at first donation visit after commencement of treatment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.17, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.15, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Deferral due to low haemoglobin: after multiple donation visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.15, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.03, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Deferral due to low haemoglobin: cumulative deferrals over all visits <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1344</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.19, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1396</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.11, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Haemoglobin (g/L): before further donation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>297</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐1.90, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.56 [0.21, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Serum ferritin (ng/mL): before further donation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.94 [1.00, 20.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>375</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>14.39 [9.90, 18.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Serum ferritin (ng/mL): after subsequent donation(s) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Males</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>142</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.70 [‐2.36, 17.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Females</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>477</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.00 [6.13, 13.87]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Iron supplementation versus placebo/control: males versus females</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Iron supplementation versus placebo/control: low risk of performance bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deferral due to low haemoglobin (primary outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Deferral at first donation visit after commencement of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.17, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Deferral after multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>541</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.22 [0.11, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cumulative deferrals over multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1820</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.18, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.76 [1.07, 8.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>594</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>13.31 [7.22, 19.40]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Iron supplementation versus placebo/control: low risk of performance bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009532-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Deferral due to low haemoglobin (primary outcome) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Deferral at first donation visit after commencement of treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>307</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.16, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Deferral after multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>211</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.15, 0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Cumulative deferrals over multiple donation visits</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>738</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.19, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Haemoglobin (g/L) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.23, 5.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Serum ferritin (ng/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Before further donation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>189</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>15.24 [12.37, 18.11]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Iron supplementation versus placebo/control: &gt; 75% randomised participants analysed</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009532.pub2/references#CD009532-tbl-0014">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009532.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD009532-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD009532-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009532-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD009532-note-0002">Hrvatski</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009532\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009532\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009532\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009532\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009532\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=18M35a5z&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009532.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009532.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009532.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009532.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009532.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727292178"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009532.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727292182"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009532.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea87cc9659377',t:'MTc0MDcyNzI5Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 